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Varicella-zoster virus (VZV) is a wide-spread neurotropic α-herpesvirus causing chickenpox 
(varicella) during primary infection and shingles (zoster) upon reactivation. During primary 
infection, VZV particles travel along neuronal microtubules via retrograde axonal transport 
from the distal axon endings to the somata of trigeminal and dorsal root ganglia DRG senso-
ry neurons where latency is established. In contrast, upon reactivation, VZ virions migrate to 
the periphery by anterograde axonal transport to promote the typical symptoms of shingles. 
In culture, VZV replicates in a highly cell-associated manner and has a narrow host range 
that limits experimental animal models and restricted our approaches for studying the axonal 
transport of the virus particles. In this study, we used a cloned bacterial artificial chromosome 
(BAC) of the European wild-type isolate of VZV HJO to generate two double VZV mutants via 
en-passant mutagenesis in which the protein of interest and the capsid protein p23 were 
fused either to the enhanced green fluorescent protein or to the monomeric red fluorescent 
protein. The generated BACs were then transfected into permissive melanoma cells in which 
the cell-associated viruses were reconstituted and high-titer cell-free virus preparations were 
generated. Productive anterograde and retrograde infections of DRG neurons were estab-
lished by the exposure to high titers of cell-free VZV of 104-105 plaque forming units/ml. 
Subsequently, we described the colocalization of the VZV immediate early tegument protein 
IE4 and the transmembrane envelope protein p65 together with p23 within axons of embryo-
nic Wistar rat DRG neurons after anterograde and retrograde infection with VZV. The antero-
grade axonal transport of VZV follows most likely a “married” model. Hence, our findings 
provide a platform for further investigations into the axonal transport mechanisms of VZV and 
into the role of the relevant viral proteins as possible medicinal intervention targets in preven-





Varizella-Zoster-Virus (VZV) ist ein weitverbreitetes neurotropes α-Herpesvirus, das Wind-
pocken (Varizellen) während der Erstinfektion und Gürtelrose (Zoster) nach der Reaktivie-
rung verursacht. Während der Erstinfektion wandern die VZV-Partikel den neuronalen Mikro-
tubuli entlang auf dem retrograden axonalen Weg von den distalen Axon-Enden bis in die 
Zellkörper der sensorischen Neurone der Trigeminus- oder Spinalganglien, wo die Latenz 
ausgebildet wird. Im Gegensatz wandern die VZ-Virionen nach der Reaktivierung in die Peri-
pherie über den anterograden axonalen Weg und führen zu den typischen Symptomen der 
Gürtelrose. In der Kultur repliziert VZV in stark zellassoziierter Weise und hat ein enges 
Wirtsspektrum, das experimentelle Tiermodelle limitiert und unsere Ansätze zur Untersu-
chung des axonalen Transports der Virus-Partikel begrenzt hat. In dieser Studie verwende-
ten wir ein kloniertes bakterielles artifizielles Chromosom (BAC) des europäischen Wildtyp-
VZV-Isolats HJO, um zwei VZV-Doppelfusionsmutanten via en-passant-Mutagenese zu er-
zeugen, in denen das betreffende Protein und das Kapsid-Protein p23 entweder mit dem ver-
stärkt grün fluoreszierenden Protein oder mit dem monomeren rot fluoreszierenden Protein 
fusioniert wurden. Die erzeugten BACs wurden in permissive Melanom-Zellen transfiziert, in 
denen zellassoziiertes Virus rekonstituiert und aus denen hochtitrige, zellfreie Viruspräpara-
tionen hergestellt wurden. Lytische anterograde und retrograde Infektionen der Spinalgang-
lien-Neuronen wurden durch hohe Titer zellfreien Virus von 104-105 Plaque-bildenden Einhei-
ten/ml erreicht. In der Folge beschrieben wir die Kolokalisation des sehr früh exprimierten 
VZV-Tegument-Proteins IE4 und des Transmembran-Hüllproteins p65 mit p23 in Axonen 
embryonaler Spinalganglien von Wistar-Ratten nach anterograder und retrograder VZV-
Infektion. Der anterograde axonale Transport des VZV folgt höchstwahrscheinlich dem 
„married“-Modell. Somit liefern unsere Ergebnisse eine Plattform für weitere Untersuchungen 
über die axonalen Transportmechanismen des VZV und über die Rolle der betroffenen vira-
len Proteine als mögliche Ziele für die pharmazeutische Intervention zur Vermeidung oder 
Heilung der VZV-Infektion und ihrer Komplikationen. 





Herpesviruses are double-stranded DNA viruses with genome sizes ranging from 120 to 230-
kilo base pairs and a virion diameter of approximately 150-200 nm. Herpesvirus infections 
are very common in humans and in a wide variety of vertebrates causing different symptoms 
specific for the individual herpesviruses. Despite the differences, all herpesviruses have a 
similar morphology and similar biological features in that they persist life-long in the host 
organism after the primary infection. During latency, the virus DNA is present in the cell as 
extrachromosomal episomes within the nucleoplasm. The production of infectious viral partic-
les remains blocked and the cells remain viable. However, stress, immunosuppression and 
other poorly defined stimuli may induce reactivation of the virus leading to new symptoms. 
So far, the eight human herpesviruses are classified into three subfamilies, namely, α-, β-, 
and γ-herpesviruses. The human α-herpesviruses are characteristic for their neurotropic fea-
tures and persistence in sensory neurons of the dorsal root ganglia. These viruses include 
the human herpesvirus 1 (herpes-simplex virus type 1, HSV-1), the human herpesvirus 2 
(herpes-simplex virus type 2, HSV-2), and the human herpesvirus 3 (varicella-zoster virus, 
VZV) (Modrow et al., 2003). 
3.2 The varicella zoster virus 
3.2.1 Clinical relevance of varicella zoster virus 
According to its morphology and genome structure, the human VZV is a member of the her-
pesvirus family and the α-herpesvirus subfamily. After primary infection, VZV causes 
chickenpox (varicella) primarily in children. Thereafter, the virus goes latent in sensory neu-
rons of the dorsal root and trigeminal ganglia. Upon the reactivation of VZV from its latent 
persistence, herpes zoster (shingles) occurs that can induce a severe, long-lasting pain 
known as postherpetic neuralgia, mostly in immunodeficient persons or in elderly people. 
VZV exhibits a typical tropism for the skin where bullous dermal lesions are formed during 
chickenpox and shingles. VZV infection is initiated mainly in the mucosal epithelial cells of 
the upper respiratory tract by aerosol transmission or, alternatively, by direct contact with 
lesions of infected skin (Cohen et al., 2007; Grose, 1981). 
Chickenpox is clinically well known and starts after an incubation period of about ten days to 
three weeks as the result of an exposure of a susceptible person to a chickenpox patient 
(Arvin, 2001). Varicella starts with fever, headache, fatigue, and abdominal pain. These 
primary symptoms last for about one to two days before itching skin lesions develop. VZV 
enters into the bloodstream in a cell-associated way, starting within the last few days of the 
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incubation period and lasting for a few days after the dermal rash emerges (Asano et al., 
1990; Gershon et al., 1978; Koropchak et al., 1989, 1991; Ozaki et al., 1986). The secondary 
VZV disease, zoster, is induced when the latent virus is reactivated from its hiding places in 
sensory ganglia leading to a cutaneous rash that is generally restricted to dermatomal areas 
of the skin which are connected to specific sensory nerves. A severe, mostly long-lasting 
pain defined as postherpetic neuralgia (Annunziato et al., 2000; Hope-Simpson, 1965; 
Schmidt et al., 2003) additionally characterizes herpes zoster. 
During chickenpox and shingles, the virus is released during lytic replication in the dermato-
mal epithelium or in respiratory mucous membranes (Chen et al., 2004). Since the respira-
tory secretions from varicella patients are highly contagious via air transmission, approxima-
tely 95% of the people in mild climates are infected with VZV up to the age of 30 years 
(Cohen et al., 2007; Sawyer et al., 1994), as long as no effective vaccination programs are 
followed. The vaccine strain Oka (v-Oka) is a live-attenuated VZV vaccine leading to dramati-
cally decreased morbidity and mortality rates for VZV infections. 
3.2.2 Structure of VZV genome 
VZV has the smallest genome of the human herpesviruses, with a linear double-stranded 
DNA genome (125 kb) which includes two unique regions, the unique long region (UL) (105 
kb) and the unique short region (US) (5.2 kb). The UL region and the US region are flanked 
terminally and internally by inverted repetitive sequences termed as terminal repeat long or 
internal repeat long (TRL/IRT) (89 bp) and terminal repeat short or internal repeat short 
(TRS/IRS) (7.3 kb), respectively (Davison & Scott, 1986). Two dominant isomers are found in 
equimolar quantities in virion DNA, since the US region exists in an equal amounts in both 








Fig. 1. Isomeric forms of the VZV genome. Isomeric variants of the linear VZV genome occurring during the 
replication process. Two of the four isomeric forms are found frequently (47.5%), whereas the other two forms are 
rare (2.5%) (Davison, 1984). 
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The VZV genome encodes approximately 72 open reading frames (ORFs), three of which 
are duplicated according to their position in the repetitive repeat short region (IRS and TRS) 
(ORF62/71, ORF63/70, ORF64/69) (Fig. 2). In addition, two origins of replication are located 
in the RS regions. Furthermore, there are five small repetitive regions (R1 to R5) distributed 
over the genome that vary in length according to different numbers of repeated sequence 
units (Davison & Scott, 1986; Hondo & Yogo, 1988). The segments R1, R2, R3, and R5 are 
located in the UL region, whereas R4 is placed in IRS between ORF62 and ORF63, and in 
TRS between ORF71 and ORF70. The R4 region is GC-rich and composed of a 27 bp unit 
that can be repeated several times (Casey et al., 1985). Various VZV strains have shown 
different numbers of repeated units (Gomi et al., 2002).The VZV genome has an unpaired G 
nucleotide at its left end and an unpaired C at its right end. This allows the circularization of 
the genome after having entered the nucleus by pairing these two single nucleotides from 
both ends (Davison, 1984). 
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Fig. 2. Genome structure of the VZV. The red colored ORFs represent the genes that are dispensable for the 
viral replication in permissive melanoma cell line MeWo. The green colored ORFs represent the genes that cause 
a severe viral replication defect of the related ORF-deletion viral mutants in MeWo and in human fetal skin organ 
culture. The blue colored ORFs are skin tropic. The gray colored ORFs are essential for the viral replication. The 
shown scheme is adapted from Zhang et al., 2010. 
3.2.3 VZV morphology and DNA replication 
The VZ virion is pleomorphic and has a diameter of 180 to 200 nm (Almeida et al., 1962). 
The VZV capsid includes one copy of the linear double-stranded DNA (dsDNA) which is 
wound up on a fibrillar protein (Furlong et al., 1972; Puvion-Dutilleul et al., 1987). The virus 
capsid is formed by twelve pentameric (penton) and 150 hexameric (hexon) capsomers in an 
icosahedral shape and has a diameter of approximately 80 to 120 nm (Almeida et al., 1962). 
The outer envelope of the virion is composed of a binary lipid membrane, which is associated 
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with different VZV-specific glycoproteins. The tegument is localized between the capsid and 
the envelope, and is described as an amorphous protein layer which is relevant for entry and 
morphogenesis of herpesviruses (Kinchington et al., 1992, 1995a,b; Stevenson et al., 1994) 
(Fig. 3). VZV enters the cell either directly by fusion of the viral envelope with the host-cell 
membrane or indirectly via endocytosis (Zerboni et al., 2014). Viral envelope proteins fuse 
with the cell membrane through mannose-6-phosphate receptors (Chen et al., 2004; Gabel 
et al., 1989) or through myelin-associated glycoprotein distributed mainly in neural tissues 
(Suenaga et al., 2010). 
 
Fig. 3. Structure of the VZV virion. The shown structure is adapted from Arvin et al., 2007. 
In addition, the extracellular domain of the VZV glycoprotein gE interacts with the insulin 
degrading enzyme (IDE) on the surface of the host-cell membrane. Blocking IDE results in a 
reduced infectivity and cell-to-cell spread of the virus. In non-human cells, the supplementary 
expression of the human IDE enhances the cellular infection with cell-free and cell-asso-
ciated VZV. Accordingly, IDE is considered to act as a cellular receptor for VZV and to also 
promote the important role of gE (Li et al., 2006). 
After entry, virions are de-enveloped, tegument proteins are released and distributed 
throughout the host-cell, and nucleocapsids are transported to the perinuclear space and 
release the viral genome into the nucleus. The initial viral gene expression is governed by 
the immediate-early (IE) proteins that have transactivating and transrepressing capabilities 
(Kinchington et al., 1995a,b). The IE proteins induce the overexpression of further IE genes 
and, subsequently, also of early (E) genes. Beside other E proteins, the viral DNA polymer-
rase and the DNA-binding protein are essential for the viral DNA replication. Later on in the 
lytic cycle, the promoters of the late (L) genes are activated which mainly encode structure 
components such as capsid proteins and glycoproteins. After replication, the viral DNA is 
packaged into preassembled nucleocapsids. The capsids are coated and de-coated by mem-
branes with glycoproteins as they cross the nuclear membrane towards the cytoplasm and 
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as they sprout into membrane vesicles from the trans-Golgi network (TGN). Approximately 9 
h post infection, nascent enveloped virions are formed, and 3 h later, many of them are 
detectable at the cell surface of infected cells (Cohen et al., 2007; Reichelt et al., 2009; 
Zerboni et al., 2014). VZV spreads from cell to cell in a highly cell-associated manner upon 
fusion of infected and uninfected cells using the same viral entry-specific glycoproteins, 
forming characteristic syncytia and multinucleated polykaryocytes followed by further virus 
spread (Grose et al., 2010; Oliver et al., 2013).  
3.2.4 Antiviral therapy and VZV vaccine 
In healthy children, chickenpox is normally not treated with antiviral drugs since the develop-
ment of an efficient antiviral immunity is intended. However, in immunosuppressed patients 
and in adults, chickenpox can induce a remarkable morbidity and mortality. Similarly, shing-
les show a much higher morbidity in immunodeficient individuals. Moreover, shingles can 
lead to long-lasting postherpetic neuralgia that can be difficult to control, especially in elderly 
people. The general use of antiviral nucleoside analogs has greatly improved the outcome 
(Arvin et al., 2007). 
The most commonly used antiviral agent is aciclovir (ACV), a guanosine analog which is a 
selective replication inhibitor of HSV and VZV (Whitley & Gnann, 1992). ACV is monophos-
phorylated by the viral enzyme thymidine kinase (TK). This reaction occurs only in infected 
cells. Cellular kinases are responsible for the diphosphorylation and triphosphorylation steps 
leading to high concentrations of ACV triphosphate in VZV-infected cells. Viral DNA synthe-
sis is suppressed by ACV triphosphate as a result of its competitive function with deoxygua-
nosine triphosphate as a viral DNA polymerase substrate and of the chain termination after 
its incorporation into the replicating virus DNA. The incorporation of ACV triphosphate into 
cellular DNA is unusual, since the cellular DNA polymerase has a much lower affinity to ACV 
triphosphate than the viral DNA polymerase (Arvin et al., 2007). However, defined mutations 
in the TK and/or DNA polymerase of VZV lead to therapy resistance to nucleoside analogs 
such as ACV (Andrei et al., 2012; Brunnemann et al., 2015). In this case, foscarnet is mostly 
used which blocks the pyrophosphate binding site leading to a suppression of viral DNA 
polymerase (Wagstaff & Bryson, 1994). 
In order to prevent individuals from varicella and herpes zoster, the live-attenuated vaccine 
strain v-Oka is generally recommended for infants and susceptible healthy persons in many 
countries including Germany (Hambleton & Gershon, 2005; Krause & Klinman, 1995, 2000). 
The v-Oka strain was developed in Japan in the early 1970s (Takahashi et al., 1974). The 
varicella vaccine has been used in the United States since 1995 and has been highly 
effective in reducing varicella incidence, morbidity, and mortality (Vázquez et al., 2001). 
Moreover, a high-dose variant of the vaccine is used to reduce zoster morbidity in latently 
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infected elderly individuals. The shingles vaccine has shown 51.3% efficacy in decreasing 
herpes zoster occurrence, 66.6% efficacy in decreasing the occurrence of postherpetic 
neuralgia (mainly due to prohibiting herpes zoster), and 61.1% efficacy in decreasing the 
zoster-associated disease burden (Oxman & Levin, 2008; Oxman et al., 2005; Sperber et al., 
1992). Although this vaccine is fully approved, it is not yet recommended for the general use 
in Germany by the permanent vaccination commission (Ständige Impfkommission, STIKO). 
Recently, in October 2017, a novel adjuvanted VZV subunit vaccine (HZ/su) against herpes 
zoster has been approved by the food and drug administration of the United States. This 
vaccine consists of the recombinant VZV glycoprotein gE and a liposome-based adjuvant 
system (AS01B) containing 3-O-desacyl-4′-monophosphoryl lipid A (MPL) and the saponin 
QS-21. This vaccine has been shown to lower the risk of shingles and postherpetic neuralgia 
in persons 50 years of age and older and also to be more effective and less expensive than 
the live-attenuated herpes zoster vaccine (Chlibek et al., 2013; Cunningham et al., 2016; Lal 
et al., 2015; Le & Rothberg, 2018). 
3.3 Axonal transport 
3.3.1 Neurons and axonal transport 
The main function of a neuron is to receive, conduct, and transport signals between the 
periphery and the central nervous system (CNS). The cell bodies of the nerve cells (somata) 
gather in clusters called ganglia which serve as communication centers between the peri-
phery and the CNS. These communications are conducted through elongated extensions of 
the somata known as axons which transmit the signals from cell to cell at specific connection 
sites called synapses. When a neuron transmits sensory signals to the CNS, it is called a 
sensory neuron. Somata of the sensory neurons are clustered in the trigeminal and dorsal 
root ganglia located outside the CNS to which they transport the sensory signals (Alberts et 
al., 1989; Kandel et al., 2013). Cellular proteins are transported along the microtubules of 
neuronal axons either in the anterograde orientation toward the axonal endings or in the 
opposite, retrograde direction toward the somata. These proteins are categorized into two 
groups according to their rates of transport. Proteins, such as adenosine triphosphatase 
ATPase, nerve growth factor (NGF), and membranous organelles are transported at rates of 
0.5-4 µm/s (fast axonal transport). Other proteins, such as actin, tubulin, and proteins of the 
cytoplasmic matrix are transported at rates of 0.01-0.05 µm/s (slow axonal transport; Lasek 
et al., 1984). These cellular proteins are transported along the microtubules of neural axons 
via two major motor proteins known as kinesins and dyneins. While kinesins are responsible 
for the anterograde axonal transport, dyneins govern mainly the retrograde axonal transport 
(Goldstein & Yang, 2000). 
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3.3.2 Axonal transport of α-herpesviruses 
For the α-herpesviruses HSV-1 and the porcine pseudorabies virus (PrV), there is the plau-
sible consensus that the viral capsid travel in retrograde direction without envelope using 
specific dynein-associated viral tegument proteins. In contrast, the anterograde axonal trans-
port mechanisms seem to be more controversial leading to the different so-called “married” 
and “unmarried” (separate) axonal transport models. This results in the open question if the 
viral capsid of a herpesvirus travels with or without envelope in the axon (Diefenbach et al., 
2008). Nevertheless, it was suggested that PrV capsids migrate according to the “married” 
model with envelope in anterograde axonal direction. Generally, a similar anterograde axonal 
transport model seems to be probable for HSV-1, assuming that both α-herpesviruses share 
the same axonal transport mechanisms (Diefenbach et al., 2008; Kratchmarov et al., 2012). 
3.3.3 Axonal transport of VZV and relevant proteins 
Unlike its close relatives HSV-1 and PrV whose axonal transport mechanisms have been 
extensively studied, the axonal transport of VZV is still poorly investigated due to the highly 
cell-associated spread of the infection in culture and the lack of an appropriate animal model 
(Steain et al., 2010). However, kinetic analysis of VZV expressing the capsid protein p23 
(encoded by ORF23) in fusion with the enhanced green fluorescent protein (eGFP) showed 
that the movement of viral capsids/virions within axons of retrogradely VZV-infected sensory 
neuron-like cells is discontinuous and bidirectional with a net retrograde motion (Grigorian et 
al., 2012). These data, which were generated with in-vitro neuron-like cells differentiated 
human embryonal stem cells, suggest consistency with the axonal dynamics of capsids/ 
virions of HSV-1 and PrV according to the homology of ORF23 to VP26 of HSV-1 and to 
UL35 of PrV (Antinone & Smith, 2010; Smith et al., 2001). 
VZV ORF65 encodes the envelope transmembrane protein type II p65 that is known to be 
neither essential for the virus replication in vitro, nor for the infection of human skin and T-
cells in vivo (Cohen et al., 2001; Niizuma et al., 2003). This protein shares the topology and 
the cellular localization in infected cells of its homologous US9 proteins of HSV-1 and PrV. 
The so called “axonal guidance” US9 proteins, in turn, play an essential role in anterograde 
transport and virus assembly in neuronal cells suggesting that VZV p65 would play the same 
role (DuRaine et al., 2017; Lyman et al., 2008, 2009; Miranda-Saksena et al., 2016). 
The immediate early protein IE4 of VZV, encoded by ORF4, is a tegument phosphoprotein 
conserved among all α-herpesviruses. It transactivates genes of all three phases of the virus 
replication cycle and was shown to be essential for the viral replication in vitro (Sato et al., 
2003). IE4 has also been marked as a potential alternative antiviral target as a nucleocyto-
plasmic shuttling protein for mRNA export (Ote et al., 2010). Furthermore, cotton rats inocu-
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lated with ORF4-null VZV revealed the critical role of IE4 in the establishment of latency in 
DRG (Cohen et al., 2005). 
Understanding the axonal transport patterns of IE4 as a component of the tegument and of 
p65 as an envelope protein would help to understand the type of axonal transport of VZV 
particles in anterograde and retrograde infections of DRG neurons. 
3.4 Mutagenesis of herpesvirus genomes 
Herpesviruses have large linear double-stranded DNA genomes, the smallest of which be-
longs to VZV with a 125 kb genome encoding approximately 72 genes (Davison & Scott, 
1986; McGeoch et al., 2006). This size of the genome hampered the development of efficient 
strategies for the manipulation of the viral genome. However, several genetic methods have 
been developed that enable the manipulation of most genes of interest. 
The method of the cosmid complementation (van Zijl et al., 1988) formed the basic step. In 
this technique, several overlapping cosmids are used, each of which harbors one part of the 
entire viral genome that can be mutated in Escherichia (E.) coli cells. At the end, all cosmid-
cloned segments of the viral genome with overlapping sequences are co-transfected into 
permissive eukaryotic cells. Due to the recombination between the overlapping homologous 
regions, the whole genome is reassembled enabling virus reconstitution with the desired 
mutations. Nevertheless, during the recombination process undesired mutations may occur, 
which are difficult to be excluded (van Zijl et al., 1988). 
Later on, the use of bacterial artificial chromosomes (BAC) made it greatly easier to study 
and manipulate the viral genes (Shizuya et al., 1992). The BAC vectors are able to carry 
foreign DNA segments up to 300 kb which permits to clone any herpesvirus genome at once. 
The vector part includes a resistance gene, an origin of replication, and all required genes 
from the bacterial F-plasmid (mini-F) that allows the BAC-DNA to be maintained in just one to 
two copies in bacterial cells. In general, the vector (mini-F) is transfected into eukaryotic 
cells, either infected with the virus, or alternatively, together with appropriately mutated viral 
cosmid clones. Through homologous recombination between the vector segment and the 
viral genome, the vector is inserted into a non-coding position of the viral DNA. Since the 
DNA is circularized during the replication process, the constructed BAC can then be extrac-
ted from the eukaryotic cells and transfected into bacterial cells (Brune et al., 2000; Messerle 
et al., 1997; Wagner et al., 2002). BACs can be specifically manipulated in bacteria by homo-
logous recombination. Based on these principles, an infectious BAC-clone was prepared 
from the wild-type isolate HJO of VZV (Schmidt, 2005; Wussow et al., 2009). 
The ET cloning method enables the specific and efficient mutagenesis of the BAC-cloned 
viral genome. Specific mutations are introduced into the viral genome via homologous re-
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combination of 50 bp sequences by the RecET proteins. In addition, a selection gene (anti-
biotic resistance gene) is required in order to allow the selection for the clones, in which the 
recombination took place. Such selection genes have often been flanked by IoxP sequences. 
These marker genes can then be eliminated through inducible Cre-recombinase activity 
(Muyrers et al., 1999; Zhang et al., 1998). 
In 2006, Tischer et al. developed another novel method, which enables the insertion of small 
or large sequences into the viral genome, or point mutations, or the deletion of entire genes 
without leaving behind any unwanted external operational sequences. This technique was 
termed “en-passant mutagenesis” and is based on two consequent, Red-protein mediated 
homologous recombination steps. 
In the case of a fusion of an ORF with a fluorescent protein, a polymerase-chain reaction 
(PCR) product is first amplified which includes a selective marker (kanamycin resistance, 
kanR), the specific recognition sequence (18 bp) for the endonuclease I-SceI, and fluorescent 
protein sequences with a homologous 50 bp-duplicated region. These segments are flanked 
by duplicated 50 bp sequences flanking the ORF fusion site. The PCR product is then 
electroporated into bacteria, namely the E. coli strain GS1783. The genome of this bacterial 
strain encodes the Red proteins exo, beta, and gam, the selection enzyme, and also the 
inducible endonuclease I-SceI. 
During the first Red recombination step, the PCR product is fused to the ORF of interest as a 
result of the homologous recombination of the homologous 50 bp sequences of the fusion 
site. The recombinant clone is then selected on agar plates containing kanamycin as selec-
tive drug. During the second Red recombination step, the endonuclease I-SceI is induced. 
Consecutively, the kanamycin resistance cassette can be removed from the selected recom-
binant after homologous recombination of the homologous 50 bp sequences of the fluores-
cent protein, resulting in the viral mutant BAC with the targeted fusion without any further 
changes (Fig. 4) (Tischer et al., 2006). 




















Fig. 4. En-passant mutagenesis. Generation of a gene fusion between a viral ORF and a fluorescent protein. 
First, a PCR product is amplified containing fluorescent protein sequences with a homologous 50 bp duplicated 
region (dash-framed regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 
50 bp homologous extensions of the corresponding ORF fusion site (red and green bars). After the first recombi-
nation, the ORF of interest is fused to the PCR product and then positive clones are selected out on agar plate 
with kanamycin. Finally, upon I-Scel induction via arabinose, a double strand break occurs at the I-Scel site cau-
sing the elimination of the kanR and a subsequent fusion of the fluorescent protein to the ORF of interest due to 
homologous recombination of the homologous regions (dash-framed highlighted boxes). The generated BAC car-
ries the targeted fusion, however, without any additional changes. The scheme is adapted from Tischer et al., 
2006. 
3.5 Aims of the study 
Varicella-zoster virus (VZV) has evolved mechanisms for its infection of sensory neurons and 
subsequent transport along microtubules of neuronal axons of the dorsal root ganglia (DRG). 
Understanding these poorly studied mechanisms is highly relevant to identify and target the 
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key viral genes and proteins in order to prevent the virus from going latent in DRG or to block 
its reactivation from latency. In the present study, embryonic Wistar rat DRG neurons shall 
be efficiently and productively infected with fluorescence-labeled double mutant models of 
VZV using compartmentalized cultivation systems, in order to trace the axonal colocalization 
of VZV proteins. For this purpose, a cloned BAC of the European wild-type genome HJO of 
VZV shall be used to generate two double mutants via en-passant mutagenesis. In these two 
double mutants, the protein of interest (IE4 or p65) and the capsid protein p23 of VZV shall 
be fused either to the enhanced green fluorescent protein (eGFP) or to the monomeric red 
fluorescent protein (mRFP). Productive anterograde and retrograde infections of DRG neu-
rons shall be achieved by the exposure to high titers of cell-free VZV of 104-105 plaque 
forming units PFU/ml. Consecutively, the axonal colocalization of IE4 and p65 together with 
the capsid protein p23 shall be observed and, accordingly, the axonal transport models of 
VZV have to be analyzed and discussed. With this regard, this study aims to open the way 
for further investigations into the axonal transport mechanisms of VZV and into the role of the 
relevant viral proteins as possible medicinal intervention targets in preventing or treating VZV 
infection and its complications. 
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4 RESULTS 
4.1 Generation of double-color viral mutant BACs 
Double fluorescence-labeled VZV was used as a model to study the colocalization patterns 
of viral proteins within axons of embryonic Wistar rat DRG neurons after anterograde and 
retrograde infections with VZV. In this study, the colocalization patterns were investigated 
concerning the tegument protein IE4 and the envelope transmembrane protein p65 of VZV 
together with the capsid protein p23 that served as an axonal reference protein, in order to 
understand more the axonal transport models of the VZV particles. For this purpose, two 
double fluorescence-tagged viral mutant BACs were at first generated in which ORF4 or 
ORF65 and ORF23 were fused either to eGFP or to mRFP moiety. 
4.1.1 BAC mutant pHJOpac-eGFP4-mRFP23 
Using the cloned European wild-type VZV BAC of HJO isolate (pHJOpac) (Wussow et al., 
2009), the viral BAC construct pHJOpac-eGFP4 was initially cloned in a previous project 
(Fig. 5, Spieckermann, Dissertation, 2013). In this construct, eGFP was fused to the N-termi-
nus of ORF4 via en-passant mutagenesis (Tischer et al., 2006). 
In the present study, pHJOpac-eGFP4 was manipulated via en-passant mutagenesis, in 
order to generate the double fluorescently labeled BAC pHJOpac-eGFP4-mRFP23 (Fig. 6). 
For this purpose, the transfer-vector pEP-mRFP1-in (Tischer et al., 2006) was used as a 
template for the amplification of a PCR product composed of the mRFP sequences, the posi-
tive selection marker (kanamycin resistance, KanR), and the I-SceI recognition site with spe-
cific primers (Tab. 15). These primers bind to the homologous extensions of the fusion site at 
the N-terminal end of ORF23 (Fig. 6, green and blue bars). The amplified PCR product (1762 
bp) was then purified and electroporated into E. coli GS1783 harboring the BAC-cloned ge-
nome of pHJOpac-eGFP4 (Fig. 6). After the first Red-recombination step, bacterial colonies 
from agar plates with kanamycin selection were tested by colony PCR for signals indicating 
the correct recombination products. This PCR was performed with two primers, one of which 
binds within the kanR gene and the other one downstream of the insertion position. DNA frag-
ments of 604 bp were visualized by gel electrophoresis and indicated colonies that carried 
the presumably correct recombination product (data not shown). 



















Fig. 5. Generation of pHJOpac-eGFP4 by en-passant mutagenesis. Using the vector pEP-EGFP-in, a PCR 
product was amplified containing eGFP sequences with a homologous 50 bp duplicated region (dash-framed 
regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp homologous 
extensions of the fusion site at ORF4 (red and blue bars). The resulted PCR product was then electroporated into 
E. coli harboring pHJOpac. After the first recombination, ORF4 was fused to the PCR product and then positive 
clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction via arabinose, a double 
strand break occurs at the I-Scel site causing the elimination of the kanR and a subsequent fusion of eGFP to the 
N-terminus of ORF4 due to homologous recombination of the homologous sequences (dash-framed regions), 
however, without leaving any additional changes in the genome. 
In order to confirm that the presumably positive colonies contain intact genomes except the 
insertion of the fusion sequences, the BAC-cloned genome of pHJOpac-eGFP4 (pG4) and 
the resulting BAC genome pHJOpac-eGFP4-mRFP23-kan (pG4R23-kan) were tested via 
restriction fragment length polymorphism (RFLP) analysis by digestion with the restriction 
enzymes HindIII and XhoI (Fig. 7). 






















Fig. 6. Generation of pHJOpac-eGFP4-mRFP23 by en-passant mutagenesis. Using the vector pEP-mRFP1-
in, a PCR product was amplified containing mRFP sequences with a homologous 50 bp duplicated region (dash-
framed regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp 
homologous extensions of the fusion site at ORF23 (green and blue bars). The resulted PCR product was then 
electroporated into E. coli harboring pHJOpac-eGFP4. After the first recombination, ORF23 was fused to the PCR 
product and then positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction 
via arabinose, a double strand break occurs at the I-Scel site causing the elimination of the kanR and a 
subsequent fusion of mRFP to the N-terminus of ORF23 due to homologous recombination of the homologous 
sequences (dash-framed regions), however, without leaving any additional changes in the genome. 
The previously confirmed positive colony (Fig. 7, pG4R23-kan) was used for the second step 
of Red-recombination. Similarly, the colonies that were grown on agar plates with arabinose 
(in order to induce I-SceI expression) and without kanamycin were tested by colony PCR 
with two primers, one of which binds within the mRFP gene and the other one downstream of 
the fusion position (Tab. 15). DNA fragments of 978 bp were observed by gel electrophoresis 
referring to putatively positive colonies (data not shown). 












































Fig. 7. RFLP analysis of pHJOpac-eGFP4-mRFP23-kan. RFLP analysis of HindIII- and XhoI-digested DNA of 
pHJOpac-eGFP4-mRFP23-kan (pG4R23-kan) in comparison to pHJOpac-eGFP4 (pG4) as control. The arrows 
indicate the DNA fragments confirming the colony harboring the expected BAC-cloned genome. Marker (M). Kilo-
base pairs (kb). 
For the confirmation of the positive colonies, RFLP analysis was performed based on restric-
tion enzyme digestion of the BAC-cloned pG4R23-kan and the resulting BAC-clones, presu-
mably of pHJOpac-eGFP4-mRFP23 (pG4R23), with HindIII and XhoI restriction enzymes 
(Fig. 8). Finally, the region was PCR-amplified flanking the OFR23 fusion site in the newly 
generated mutant BAC pHJOpac-eGFP4-mRFP23. The sequence analysis did not show 
mutations at the fusion site and in its flanking region (data not shown). This indicated that this 
construct was appropriate for the further experiments. 


















































Fig. 8. RFLP analysis of pHJOpac-eGFP4-mRFP23. RFLP analysis of HindIII- and XhoI-digested DNA of 
pHJOpac-eGFP4-mRFP23 (pG4R23) in comparison to pHJOpac-eGFP4-mRFP23-kan (pG4R23-kan) as control. 
The arrows indicate the presence or absence of DNA fragments confirming the colony harboring the expected 
BAC-cloned genome. 
4.1.2 BAC mutant pHJOpac-eGFP23-mRFP4 
The second construct also carried two different fused reading frames, the first one between 
eGFP and ORF23 and the second one between mRFP and ORF4. Starting again with the 
cloned BAC of the wild-type HJO of VZV (pHJOpac), the viral BAC construct pHJOpac-
eGFP23 was initially cloned via en-passant mutagenesis, in which eGFP was fused to the N-
terminus of ORF23 (Fig. 9, Spieckermann, Dissertation, 2013).  
Here, pHJOpac-eGFP23 was manipulated via en-passant mutagenesis, in order to generate 
the double fluorescently labeled BAC pHJOpac-eGFP23-mRFP4 (Fig. 10). For this purpose, 
the transfer-vector pEP-mRFP1-in was used as a template for the amplification of a PCR 
product composed of the mRFP sequences, the positive selection marker (kanamycin resi-
stance, KanR), and the I-SceI recognition site with specific primers (Tab. 15). These primers 
bind to the homologous extensions of the fusion site at the N-terminal end of ORF4 (Fig. 10, 
green and blue bars). 



















Fig. 9. Generation of pHJOpac-eGFP23 by en-passant mutagenesis. Using the vector pEP-EGFP-in, a PCR 
product was amplified containing eGFP sequences with a homologous 50 bp duplicated region (dash-framed 
regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp homologous 
extensions of the fusion site at ORF23 (red and blue bars). The resulted PCR product was then electroporated 
into E. coli harboring pHJOpac. After the first recombination, ORF23 was fused to the PCR product and then 
positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction via arabinose, a 
double strand break occurs at the I-Scel site causing the elimination of the kanR and a subsequent fusion of eGFP 
to the N-terminus of ORF23 due to homologous recombination of the homologous sequences (dash-framed 
regions), however, without leaving any additional changes in the genome. 
The amplified PCR product (1821 bp) was then purified and electroporated into E. coli 
GS1783 harboring the BAC-cloned genome of pHJOpac-eGFP4 (Fig. 10). After the first Red-
recombination step, bacterial colonies from agar plates with kanamycin selection were tested 
by colony PCR for signals indicating the correct recombination products. This PCR was 
performed with two primers, one of which binds within the kanR gene and the other one 
downstream of the insertion position. DNA fragments of 662 bp were visualized by gel elec-
   RESULTS 
20 
trophoresis and indicated colonies that carried the presumably correct recombination product 






















Fig. 10. Generation of pHJOpac-eGFP23-mRFP4 by en-passant mutagenesis. Using the vector pEP-mRFP1-
in, a PCR product was amplified containing mRFP sequences with a homologous 50 bp duplicated region (dash-
framed regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp 
homologous extensions of the fusion site at ORF4 (green and blue bars). The resulted PCR product was then 
electroporated into E. coli harboring pHJOpac-eGFP23. After the first recombination, ORF4 was fused to the PCR 
product and then positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction 
via arabinose, a double strand break occurs at the I-Scel site causing the elimination of the kanR and a subse-
quent fusion of mRFP to the N-terminus of ORF4 due to homologous recombination of the homologous se-
quences (dash-framed regions), however, without leaving any additional changes in the genome. 
In order to confirm that the presumably positive colonies contain intact genomes except the 
insertion of the fusion sequences, the BAC-cloned genome of pHJOpac-eGFP23 (pG23) and 
the resulting BAC genome pHJOpac-eGFP23-mRFP4-kan (pG23R4-kan) were tested via 
RFLP analysis by digestion with the restriction enzymes BglII and XhoI (Fig. 11). 











































Fig. 11. RFLP analysis of pHJOpac-eGFP23-mRFP4-kan. RFLP analysis of BglII- and XhoI-digested DNA of 
pHJOpac-eGFP23-mRFP4-kan (pG23R4-kan) in comparison to pHJOpac-eGFP23 (pG23) as control. The arrows 
indicate the DNA fragments confirming the colony harboring the expected BAC-cloned genome. 
The previously confirmed positive colony (Fig. 11) was used for the second step of Red-re-
combination. Similarly, the colonies that were grown on agar plates with arabinose (in order 
to induce I-SceI expression) and without kanamycin were tested by colony PCR with two pri-
mers, one of which binds within the mRFP gene and the other one downstream of the fusion 
position (Tab. 15). DNA fragments of 878 bp were observed by gel electrophoresis referring 
to putatively positive colonies (data not shown). For the confirmation of the positive colonies, 
RFLP analysis was performed based on restriction enzyme digestion of the BAC-cloned 
pG23R4-kan and the resuling BAC-clones, presumably of pHJOpac-eGFP23-mRFP4 
(pG23R4), with BglIII and XhoI restriction enzymes (Fig. 12). Finally, the region was PCR 
amplified flanking the OFR4 fusion site in the newly generated viral mutant BAC pHJOpac-
eGFP23-mRFP4. The sequence analysis showed no mutations at the fusion site and in its 
flanking region (data not shown). This indicated that this construct was appropriate for the 
further experiments. 


















































Fig. 12. RFLP analysis of pHJOpac-eGFP23-mRFP4. RFLP analysis of BglII- and XhoI-digested DNA of 
pHJOpac-eGFP23-mRFP4 (pG23R4) in comparison to pHJOpac-eGFP23-mRFP4-kan (pG23R4-kan) as control. 
The arrows indicate the presence or absence of DNA fragments confirming the colony harboring the expected 
BAC-cloned genome. 
4.1.3 BAC mutant pHJOpac-eGFP23-4mRFP 
As described above for the previously generated BAC pHJOpac-eGFP23-mRFP23 (Fig. 10), 
the next double-labeled BAC was cloned from pHJOpac-eGFP23 via en-passant mutagene-
sis, however, in which mRFP was fused to the C-terminal end of ORF4 to generate the doub-
le fluorescence-tagged BAC pHJOpac-eGFP23-4mRFP (Fig. 13). In order to clone this con-
struct, pEP-mRFP1-in transfer-vector was used as a template for the amplification of a PCR 
product composed of the mRFP sequences, the positive selection marker (kanamycin resi-
stance, KanR), and the I-SceI recognition site with specific primers (Tab. 15). These primers 
bind to the homologous extensions of the fusion site at the C-terminus of ORF4 (Fig. 13, 
green and blue bars). 






















Fig. 13. Generation of pHJOpac-eGFP23-4mRFP by en-passant mutagenesis. Using the vector pEP-mRFP1-
in, a PCR product was amplified containing mRFP sequences with a homologous 50 bp duplicated region (dash-
framed regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp 
homologous extensions of the fusion site at ORF4 (green and blue bars). The resulted PCR product was then 
electroporated into E. coli harboring pHJOpac-eGFP23. After the first recombination, ORF4 was fused to the PCR 
product and then positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction 
via arabinose, a double strand break occurs at the I-Scel site causing the elimination of the kanR and a 
subsequent fusion of mRFP to the C-terminal end of ORF4 due to homologous recombination of the homologous 
sequences (dash-framed regions), however, without leaving any additional changes in the genome. 
The amplified PCR product (1821 bp) was then purified and electroporated into E. coli 
GS1783 harboring the BAC-cloned genome of pHJOpac-eGFP4 (Fig. 13). After the first Red-
recombination step, bacterial colonies from kanamycin selection agar plates were tested by 
colony PCR for signals indicating the correct recombination products. This PCR was perfor-
med with two primers, one of which binds within the kanR gene and the other one upstream 
of the insertion position. DNA fragments of 684 bp were visualized by gel electrophoresis and 
indicated colonies that carried the presumably correct recombination product (data not 
shown). 




















































Fig. 14. RFLP analysis of pHJOpac-eGFP23-mRFP4. RFLP analysis of HindIII- and XhoI-digested DNA of 
pHJOpac-eGFP23-4mRFP (pG23-4R) in comparison to pHJOpac-eGFP23-4mRFP-kan (pG23-4R-kan) as con-
trol. The arrows indicate the absence of DNA fragments confirming the colony harboring the expected BAC-
cloned genome. 
In order to confirm that the presumably positive colonies contain intact genomes except the 
insertion of the fusion sequences, the BAC-cloned genome of pHJOpac-eGFP23 and the 
resulting BAC genome pHJOpac-eGFP23-4mRFP-kan were tested via RFLP analysis by 
digestion with the restriction enzymes HidIII and XhoI. Confirmed positive colonies were then 
used for the second step of Red-recombination. Similarly, the colonies that were grown on 
agar plates with arabinose (in order to induce I-SceI expression) and without kanamycin 
were tested by colony PCR with two primers, one of which binds within the mRFP gene and 
the other one upstream of the fusion position (Tab. 15). DNA fragments of 1454 bp were 
observed by gel electrophoresis referring to putatively positive colonies (data not shown). For 
the confirmation of a correct mutagenesis of the generated mutants, RFLP analysis was 
performed based on restriction enzyme digestion of the BAC-cloned pHJOpac-eGFP23-
4mRFP-kan (pG23-4R-kan) and the resuling BAC-clones, presumably of pHJOpac-eGFP23-
4mRFP (pG23-4R), with HindIII and XhoI restriction enzymes (Fig. 14). For additional 
confirmation of a correct mutagenesis of the final double fluorescence-labeled pG23-4R, 
RFLP analysis was performed based on restriction enzyme digestion of the BAC-cloned 
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pHJOpac (pHJO), pG23, pG23-4R-kan, and pG23-4R with HindIII and XhoI restriction 



























































Fig. 15. En-passant mutagenesis confirmation via RFLP analysis. RFLP analysis of HindIII- and XhoI-dige-
sted DNA of pG23, pG23-4R-kan, and pG23-4R in comparison to the wild-type pHJOpac (pHJO) as control. The 
arrows indicate the presence or absence of DNA fragments confirming the correct mutagenesis of the expected 
BAC-cloned genomes. 
Finally, the region was PCR amplified flanking the OFR4 fusion site in the newly generated 
viral mutant BAC pHJOpac-eGFP23-4mRFP. The sequence analysis showed no mutations 
at the fusion site and in its flanking region (data not shown). This indicated that this construct 
was appropriate for the further experiments. 
4.1.4 BAC mutant pHJOpac-eGFP65-mRFP23 
This construct was completely generated by our group in a previous project (Spieckermann, 
Dissertation, 2013) and used in this study for further experiments. In brief, similar recombi-
neering techniques were used to generate the double color mutant BAC pHJOpac-eGFP65-
mRFP23 (Fig. 16, 17). 



















Fig. 16. Generation of pHJOpac-eGFP65 by en-passant mutagenesis. Using the vector pEP-EGFP-in, a PCR 
product was amplified containing eGFP sequences with a homologous 50 bp duplicated region (dash-framed 
regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp homologous 
extensions of the fusion site at ORF65 (red and blue bars). The resulted PCR product was then electroporated 
into E. coli harboring pHJOpac. After the first recombination, ORF65 was fused to the PCR product and then 
positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel induction via arabinose, a 
double strand break occurs at the I-Scel site causing the elimination of the kanR and a subsequent fusion of eGFP 
to the N-terminus of ORF65 due to homologous recombination of the homologous sequences (dash-framed 
regions), however, without leaving any additional changes in the genome. 






















Fig. 17. Generation of pHJOpac-eGFP65-mRFP23 by en-passant mutagenesis. Using the vector pEP-
mRFP1-in, a PCR product was amplified containing mRFP sequences with a homologous 50 bp duplicated region 
(dash-framed regions), a positive selection marker (kanR), and an I-Scel recognition site with primers of two 50 bp 
homologous extensions of the fusion site at ORF23 (green and blue bars). The resulted PCR product was then 
electroporated into E. coli harboring pHJOpac-eGFP65. After the first recombination, ORF23 was fused to the 
PCR product and then positive clones were selected out on agar plate with kanamycin. Finally, upon I-Scel 
induction via arabinose, a double strand break occurs at the I-Scel site causing the elimination of the kanR and a 
subsequent fusion of mRFP to the N-terminal end of ORF23 due to homologous recombination of the 
homologous sequences (dash-framed regions), however, without leaving any additional changes in the genome. 
4.2 Virus reconstitution from cloned VZV-BACs 
4.2.1 Lipofection of cloned VZV-BACs into permissive melanoma cells 
All BAC-cloned VZV genomes were extracted from E. coli by alkaline lysis and then lipo-
fected using Lipofectamine 2000 into permissive human MeWo melanoma cells. The recon-
stitution and the replication of the viral variants in the permissive MeWo cells were establi-
shed upon formation of viral cytopathogenic effects (CPEs) under the tissue culture micro-
scope. After detection of first CPEs (approximately 5-10 d post-transfection, dpt), the trans-
fected MeWo cells were passaged several times. Since VZV is a cell-associated virus, the 
infected MeWo cells harboring the infectious viral mutants were later on harvested, portioned 
into samples, and finally stored frozen at -80°C for further analysis. The first two double 
fluorescence-tagged VZV mutant BACs pHJOpac-eGFP4-mRFP23 and pHJOpac-eGFP23-
mRFP4 did not show any CPEs after lipofection into permissive melanoma cells and even 
after several passaging. In order to assure that these BACs are not reconstitutable, the nuc-
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leofection technique was additionally applied. After yielding the same results, these cloned 
BACs were confirmed to be replication-incompetent. In contrast, the cloned wild-type BAC 
pHJOpac and the two generated double fluorescently labeled VZV mutant BACs pHJOpac-
eGFP23-4mRFP and pHJOpac-eGFP65-mRFP23 were confirmed to be replication-compe-
tent upon observing CPEs at 5-10 dpt using the lipofection technique. These three viral re-
combinants were termed HJO, G23-4R, and G65R23, respectively, and then used for further 
analysis and experiments. 
4.2.2 Replication kinetics of the replication-competent virus variants 
In order to study the replication kinetics of all described reconstitutable viral variants, the pre-
served infected MeWo cells were used at first for the quantification of the virus load. After the 
number of plaque forming units (PFU) of each viral variant from the preserved samples had 
been quantified, replication kinetics of all recombinant viruses were performed and analyzed 
in comparison to those of the wild-type HJO. The total result of three independent experi-
ments did not show relevant differences and this was even more obvious after normalization 
of all initial PFU/ml values to 100 (Fig. 18). These independent experiments were conducted 
by using three separate samples of each viral variants. In each experiment, the virus titers 
were performed in four separate cultures for each viral variant. The infected MeWo cells 
were then harvested daily until d5 post-infection (pi). Thereafter, the PFU of the harvested 
infected MeWo cells from each day (d1 through d5) were counted using the fluorescence 
microscope. In parallel, cultured uninfected MeWo cells were infected with 100 PFU/ml of 
each viral variant on the first day of the experiment to determine the virus titers at 0 dpi. 
Finally, the resulting PFU values of each viral variant were analyzed (Tab. 1-5, Fig. 18). 
Tab. 1. Plaque forming units (PFU)/ml of wild-type HJO for five days after infection of MeWo cells 
HJO d0 d1 d2 d3 d4 d5 
sample 1 1 120 300 3,000 1,000 4,000 7,000 
 2 110 200 4,000 4,000 2,000 8,000 
 3 90 250 4,000 4,000 6,000 9,000 
 4 120 300 2,000 3,000 1,000 8,000 
sample 2 1 70 100 1,500 10,000 20,000 7,000 
 2 60 100 1,200 8,000 20,000 12,000 
 3 40 80 1,500 14,000 20,000 4,000 
 4 10 30 1,100 7,000 20,000 9,000 
sample 3 1 50 80 1,200 4,000 5,000 6,000 
 2 70 80 1,600 3,000 8,000 4,000 
 3 50 90 1,200 6,000 8,000 8,000 
 4 50 80 1,600 5,000 10,000 6,000 
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Tab. 2. Plaque forming units (PFU)/ml of G23 for five days after infection of MeWo cells 
G23 d0 d1 d2 d3 d4 d5 
sample 1 1 110 300 400 4,000 4,000 2,000 
 2 80 200 1,000 7,000 10,000 3,000 
 3 140 100 500 3,000 5,000 2,000 
 4 70 100 400 6,000 10,000 3,000 
sample 2 1 50 100 800 2,000 10,000 7,000 
 2 80 100 700 5,000 16,000 6,000 
 3 130 280 300 5,000 7,000 4,000 
 4 90 120 300 1,000 13,000 6,000 
sample 3 1 110 40 1,100 4,000 10,000 7,000 
 2 60 70 900 2,000 12,000 6,000 
 3 120 30 500 2,000 9,000 8,000 
 4 120 40 700 5,000 5,000 9,000 
Tab. 3. Plaque forming units (PFU)/ml of G23-4R for five days after infection of MeWo cells 
G23-4R d0 d1 d2 d3 d4 d5 
sample 1 1 140 200 800 1,000 5,000 2,000 
 2 120 300 700 2,000 6,000 4,000 
 3 90 300 500 4,000 13,000 5,000 
 4 60 100 600 6,000 7,000 3,000 
sample 2 1 110 200 200 1,700 6,000 2,500 
 2 110 200 500 2,000 5,000 2,500 
 3 90 100 300 2,000 2,700 2,500 
 4 50 70 500 2,000 3,300 2,500 
sample 3 1 60 50 300 10,000 2,400 3,000 
 2 40 50 200 9,000 2,200 2,300 
 3 60 100 400 8,000 5,000 2,400 
 4 50 40 500 14,000 2,200 2,200 
Tab. 4. Plaque forming units (PFU)/ml of G65 for five days after infection of MeWo cells 
G65 d0 d1 d2 d3 d4 d5 
sample 1 1 80 200 700 2,000 3,000 4,000 
 2 90 400 1,300 5,000 5,000 4,000 
 3 30 100 1,200 5,000 6,000 5,000 
 4 60 200 1,000 4,000 7,000 4,000 
sample 2 1 80 150 500 4,000 7,000 1,000 
 2 50 300 700 2,000 2,000 1,900 
 3 40 100 200 2,000 6,000 1,000 
 4 70 200 1,100 3,000 7,000 1,200 
sample 3 1 40 50 900 4,000 6,000 8,000 
 2 30 120 1,000 2,400 1,000 6,000 
 3 50 130 1,200 2,000 4,000 7,000 
 4 60 90 1,400 3,000 2,000 4,000 
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Tab. 5. Plaque forming units (PFU)/ml of G65R23 for five days after infection of MeWo cells 
G65R23 d0 d1 d2 d3 d4 d5 
sample 1 1 50 50 400 2,000 5,000 4,000 
 2 70 100 400 4,000 3,000 2,000 
 3 50 100 400 2,000 2,000 2,000 
 4 60 50 500 1,000 3,000 1,500 
sample 2 1 40 200 800 1,400 6,000 900 
 2 50 80 700 1,500 6,000 1,000 
 3 50 100 300 2,000 3,000 2,000 
 4 30 200 300 1,200 3,000 600 
sample 3 1 30 70 100 200 600 600 
 2 10 70 100 400 1,000 700 
 3 40 80 300 400 500 1,000 












Fig. 18. Replication kinetics of recombinant viruses derived from HJO, G23, G23-4R, G65, and G65R23. (A) 
The replication curves of the generated VZV recombinants compared to those of the wild-type HJO do not show 
relevant differences. At d0, permissive MeWo cells were infected with 100 PFU/ml of each variant in 6-well dishes 
in triplicates at separate intervals. The infected MeWo cells were then harvested daily until 5 dpi. The harvested 
MeWo cells were then used to infect 50% confluent permissive MeWo cells seeded in 24-well dishes for the titer 
quantification. The PFU titers of each day were measured each time from four parallel cell cultures in each case. 
The PFUs were counted under the fluorescence microscope and the values from the triplicate results were 
averaged. The replication curves were generated after plotting the logarithmic values of the averages against the 
day post infection values. Error bars represent standard deviation for three replicates. (B) The replication curves 
after normalizing the previous results to the value of 100 PFU/ml at 0 dpi. This result did not show again relevant 
differences of the replication kinetics of all viral variants. 
4.2.3 Confirmation of the correct fusion sites from total DNA of permissive cells 
In order to confirm that the generated double fluorescently tagged viruses carry the expected 
fusions, isolated DNA from infected melanoma cells MeWo was analyzed by PCR. Since 
VZV is highly cell-associated, infected MeWo cells with each viral mutant were harvested 
and the total DNA was isolated. Afterwards, PCR fragments from each isolate were amplified 
with primers flanking the protein-protein fusion sites of G23, 4R, G65, and R23 (Tab. 15). 
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After analysis of the viral DNA fragment sizes of the protein-protein fusions, all fused protein-













Fig. 19. PCR analysis of recombinant viruses. PCR analysis of G23-4R and G65R23 genomes in comparison 
to their intermediate products G23 and G65, respectively (upper line of the labeling on top). The amplified PCR 
products (lower line of the labeling on top) of the total DNA isolated from infected MeWo cells using primers 
flanking the fusion sites confirm the validity of the final virus recombinants G23-4R and G65R23. (A) PCR 
analysis of G23 with primers flanking the fusion sites G23 and 4R yielded one DNA fragment of 871 bp referring 
to the fusion site of G23 (first two lanes after the marker M). PCR analysis of G23-4R with primers flanking the 
same fusion sites yielded two DNA fragments 871 bp and 681 bp referring to the fusion sites of G23 and 4R, 
respectively, confirming the validity of the first double fluorescent mutant G23-4R (second two lanes). (B) PCR 
analysis of G65 with primers flanking the fusion sites G65 and R23 yielded one DNA fragment of 973 bp referring 
to the fusion site of G65 (first two lanes after the marker M). PCR analysis of G65-R23 with primers flanking the 
same fusion sites yielded two DNA fragments 973 bp and 254 bp referring to the fusion sites of G65 and R23, 
respectively, confirming the validity of the second double fluorescent mutant G65-R23 (second two lanes). 
4.2.4 Fusion gene transcription from permissive melanoma cells 
Total RNA was isolated from infected MeWo melanoma cells for the control of the viral gene 



















Fig. 20. RT-PCR analysis of recombinant viruses. RT-PCR analysis of G23-4R and G65R23 transcripts in 
comparison to that of the recombinant wild-type HJO (upper line of the labeling on top). The amplified RT-PCR 
products (lower line of the labeling on top) of the total RNA isolated from infected MeWo cells using primers 
flanking the fusion sites confirm the validity of the generated G23-4R and G65R23 virus recombinants. GAPDH 
(540 bp) served as a cellular control and the analysis was performed in the presence (+) or absence (-) of reverse 
transcriptase. (A) RT-PCR analysis of G23-4R with primers flanking the fusion sites G23 and 4R yielded DNA 
fragments of 871 bp and 681 bp, respectively (arrows). (B) RT-PCR analysis of G65-R23 with primers flanking the 
fusion sites G65 and R23 yielded DNA fragments of 973 bp and 254 bp, respectively (arrows). 
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After isolation, RNA samples were treated with deoxyribonuclease I (DNAse I), in order to 
degrade the residual chromosomal and viral DNA prior to complementary cDNA synthesis. 
Finally, reverse transcriptase (RT) PCR analysis of cDNA was performed in parallel with 
control samples without RT treatment showing relevant bands of all viral fusion gene 
expression in G23-4R and G65R23. However, as expected, bands were not detected for the 
viral fusion gene expression in the wild-type HJO. Furthermore, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) transcripts were detected as a positive cellular reference in all 
samples confirming the correct cDNA synthesis (Fig. 20). 
4.2.5 Viral fusion protein expression via immunoblot analysis 
For the detection of the viral proteins in infected permissive cells, protein lysates of G23-4R- 
and G65R23-infected MeWo melanoma cells were subjected to sodium dodecyl sulfate 
(SDS) polyacrylamide gel electrophoresis and detected with anti-GFP and anti-RFP antibo-















Fig. 21. Immunoblot analysis of recombinant viruses. Immunoblot of protein lysates from infected versus unin-
fected MeWo cells with antibodies to mRFP (27 kDa), eGFP (27 kDa), VZV-gI (53-100 kDa) as a viral control, or 
β-actin (45 kDa) as a cellular control show valid expression bands of all fusion proteins G23/R23 (52-60 kDa), 4R 
(78 kDa), and G65 (33-40 kDa). Lysates from MeWo cells infected with an mRFP-expressing VZV Oka strain and 
from HeLa cells transfected with an expression vector of eGFP-β-actin (72 kDa) fusion protein were used to 
control the expression of the mRFP and eGFP moiety, respectively (lanes 5, 6). Uninfected MeWo and HeLa cells 
did not show relevant proteins bands (lanes 1, 7). 
As expected, the G23 fusion protein was detected at approximately 52-60 kDa, referring to 
the non-phosphorylated and the phosphorylated forms of p23 fused to 27 kDa of eGFP (Fig. 
21, lane 3) and a similar size was observed for the R23 fusion protein (Fig. 21, lane 4). For 
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the fluorescence-labeled immediate-early fusion protein 4R, the immunoblot yielded a 78 
kDa band of mRFP fused to 51 kDa of IE4 and an additional weak signal at approximately 27 
kDa probably related to non-fused mRFP (Fig. 21, lane 3). For the fusion protein G65, the 
immunoblot showed two bands which are likely to result from differential phosphorylation 
(Fig. 21, lane 4). As viral and cellular controls, anti-VZV-gI and anti-β-actin antibodies were 
applied in addition to mRFP and eGFP controls (Fig. 21, lanes 5, 6). However, lysates from 
non-infected cells did not show relevant protein expression (Fig. 21, lanes 1, 7). 
4.3 Cellular localization of viral fusion proteins 
4.3.1 Intracellular localization of IE4, p65, and p23 in non-neuronal cells 
Permissive MeWo melanoma and HFF fibroblast cells were propagated on coverslips and in-
oculated with G23-4R, G65R23, or G65 to demonstrate the localization patterns of the fusion 
proteins. Accordingly, infected cells were fixed at 2 dpi and stained with Hoechst 33342, then 
monitored by confocal imaging (Fig. 22). 
The capsid protein p23 is expected to localize in the nucleus of infected cells, since it was 
suggested to play a role in the nuclear transport of viral proteins during virus replication and 
also to be situated within the nuclear promyelocytic leukemia PML cages (Chaudhuri et al., 
2008; Reichelt et al., 2011). Consistently, the G23 and R23 proteins were detected within the 
nucleus with a strong expression and only weak punctuated signals were found in the cyto-
plasm of infected MeWo melanoma and HFF fibroblast cells (Fig. 22). 
The fusion protein 4R was distributed more often in the cytoplasm than in the nucleus of in-
fected MeWo and fibroblast cells at 2 dpi (Fig. 22). This result is consistent with the assump-
tion that during the early state of infection IE4 is located in the nucleus, then during ongoing 
infection it is distributed to the cytoplasm (Cohen et al., 2005; Lungu et al., 1998; Ote et al., 
2010), which concludes that at 2 dpi more cells have switched to the late state of infection. 
In the case of the transmembrane protein p65, the fusion protein G65 of the double mutant 
G65R23 was detected on the surface of the infected cells and also in perinuclear structures 
as expected for such type II membrane protein which had been described also in the trans-
Golgi network (TGN) (Lyman et al., 2009) (Fig. 22). In order to confirm the TNG localization, 
G65-infected MeWo and fibroblast cells were fixed at 2 dpi, then stained with the anti golgin-
97 antibody as TGN marker before nuclear staining with Hoechst 33342. The TGN localiza-
tion of G65 was confirmed upon observing accumulation signals of G65 expression at the 
distribution sites of the golgin-97 TGN marker (Fig. 23). However, viral signals were not 
detected in non-infected MeWo and fibroblast cells (Fig. 22, 23). 





















































Fig. 22. Intracellular localization of IE4, p65, and p23 in permissive non-neuronal cells. Fibroblasts and 
MeWo cells were infected with the virus recombinants G23-4R or G65R23, then fixed, stained with Hoechst 
33342, and visualized by Olympus fluorescence confocal microscopy at 2 dpi. The first four images on the left 
side show the merged images of the same viral recombinants with the nuclear Hoechst stain. The following 
images on the right side show unmerged and merged magnifications of the white-framed area. The lower two 
panels show the results of mock-infected cells. Scale bar of the original images, 20 μm. 


































Fig. 23: p65 distribution in permissive non-neuronal cells. Fibroblasts and MeWo melanoma cells were 
infected with G65 recombinant virus, then fixed, permeabilized, stained with anti golgin-97 and Hoechst 33342, 
and visualized by Olympus fluorescence confocal microscopy at 2 dpi. The first two images on the left side show 
the merged images of G65 with TGN stain and the nuclear stain Hoechst 33342. The following images on the 
right side show unmerged and merged magnifications of the white-framed area. The lower two panels show the 
results of uninfected cells. Scale bar of the original images, 20 μm. 
4.3.2 Localization of IE4, p65, and p23 in neurons 
DRG-derived sensory neurons from d18 rat embryos (E18) were co-cultivated with G23-4R 
or G65R23 infected fibroblasts within channels of ibidi µ-slides 60.4. At 2 dpi, cells were fixed 
and stained for the immunofluorescence analysis. The G23 and R23 fusion proteins were lo-
calized predominantly in the nucleus of infected sensory neurons with only weak punctuated 
expression in the cytoplasm, consistent with the previous observation for p23 in infected neu-
rons at 3-7 dpi (Markus et al., 2011). In contrast, the G65 fusion protein was only detectable 
in the cytoplasm of infected sensory neurons (Fig. 24). 



































Fig. 24: Localization of IE4, p65, and p23 in neuronal cells. (A) Sensory neurons were co-cultured with G23-
4R- and G65R23-infected fibroblasts, then fixed, permeabilized, stained with TO-PRO-3 and anti βlll-tubulin, and 
visualized by Zeiss fluorescence confocal microscopy at 2 dpi. The first two images on the left side show the mer-
ged images of the viral recombinants with the nuclear stain TO-PRO3 and the neuron-specific stain anti βIII-tubu-
lin. The following images on the right side show unmerged and merged magnifications of the white-framed area. 
(B) Similarly, co-infected sensory neurons were fixed, stained with Hoechst 33342, and visualized by Keyence 
fluorescence microscopy at 2 dpi. Scale bar of the original images, 20 μm. 
In latently infected neurons, IE4 had been suggested to localize only to the cytoplasm, 
whereas its expression was distributed almost alike between the nucleus and cytoplasm 
upon reactivation (Gershon et al., 2008; Lungu et al., 1998). However, in productively infec-
ted sensory neurons of E18, 4R expression was predominantly but not exclusively in the cy-
toplasm (Fig. 24), which is largely consistent with the spreading pattern of 4R expression in 
non-neuronal cells explained above. In this respect, we consider the infection state of E18 
sensory neurons to be rather lytic than latent, due to the observed neuronal death at later 
times after infection, the spreading pattern of the infection, and the expression of the late 
capsid protein p23 which is typical for the lytic replication and does not belong to the latently 
expressed VZV proteins (Cohrs et al., 1996, 2003; Kennedy et al., 1999; Meier et al., 1993). 
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4.4 Axonal colocalization of viral fusion proteins 
4.4.1 Axonal co-transport of IE4, p65, and p23 after anterograde infection of DRG 
neurons with VZV 
The compartmentalized DRG cell cultivation system with two chambers separated by a 17 
mm long channel filled with agarose had been efficiently used before to study the axonal 
transport of rabies virus (Bauer et al., 2014). This system allowed us to monitor the colocali-
zation of IE4 and p65 with the small capsid protein p23 within axons of E18 rat embryos 
DRG neurons. Freshly prepared DRG cells were seeded into the somal chamber (proximal) 
and the axons were allowed to grow through the agarose-filled channel for approximately 4 
weeks until they reached the distal axonal chamber supported by a 10-fold NGF concentra-
tion in the distal compartment (Fig. 5A). 
For the anterograde infection, DRG cells were inoculated in the proximal chamber with high 
titers of cell-free G23-4R or G65R23 for 2-3 h and then further cultivated in virus-free medi-
um. Subsequently, the live axons in the middle of the channel were monitored for fluorescent 
signals of VZV proteins and potential protein-protein colocalizations by BZ-9000 Keyence 
fluorescence microscope. Apparently, fluorescent signals were too weak to be detectable by 
our microscope at 0-1 dpi. However, several axons in the middle of the channel were detec-
table with respective fluorescence signals from 2 dpi, and at 3 dpi most axons were filled with 
fluorescent particles (Fig. 5B, C). Based on daily observations, infected axons collapsed at 
approximately 10 dpi (data not shown) confirming the productive infection type and the axo-
nal spread of the virus. At 3 dpi, almost all green spots of G23 expression were noticed to 
coincide with the red 4R signals within axons of anterogradely infected DRG cells (Fig. 5B). 
Similar colocalization patterns were also observed for G65 and R23 (Fig. 5C), together sug-
gesting a simultaneous transport of IE4 and p65 with the VZV capsid during anterograde 
infection in DRG cells. 











G65 R23 merge¹ merge²G65R23C
 
Fig. 25. Axonal colocalization of IE4, p65, and p23 after anterograde infection of DRG neurons. (A) Embry-
onic rat DRG cells were seeded into the proximal chamber (somal site) and axons were allowed to grow through a 
0.5% agarose-filled channel toward the distal chamber for 3-4 weeks. Anterograde and retrograde infections of 
DRG cells at the proximal or the distal chamber, respectively, allowed tracing of the axonal colocalization of the 
fluorescence-tagged VZV proteins. Axons in the middle of the channel were daily live-monitored and protein-pro-
tein colocalizations were imaged by Keyence fluorescence microscope at 3 dpi. (B) The first two images on the 
left side show the merged images of axons of G23-4R-infected DRG neurons followed by unmerged and merged 
magnification of the white-framed area from two independent observations. Arrowheads highlight a number of p23 
(green) colocalization signals with IE4 (red). Colocalization was confirmed after observation of closely neighboring 
G23 and 4R identical signals upon slight shifting of the images before merging (lower panel). (C) Analogous ob-
servations for axons of G65-R23-infected DRG neurons. Scale bar of the original image, 20 µm. 
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4.4.2 Axonal colocalization of IE4, p65, and p23 after retrograde infection of DRG 
neurons with VZV 
Similar to the anterograde infection, 3-4 week grown DRG neurons were cultivated in the dis-
tal chamber with high titers of cell-free G23-4R or G65R23 for 2-3 h and then further cultiva-
ted in virus-free medium. Thereafter, the live axons in the middle of the channel were monito-
red for fluorescent signals of VZV proteins and potential protein-protein colocalizations and 
noted at 3 dpi by BZ-9000 Keyence fluorescence microscope (Fig. 26). At 3 dpi, almost all 
green signals of G23 expression were observed coinciding with the red 4R signals within 
axons of retrogradely infected DRG cells (Fig. 26A). Similar colocalization patterns were also 
observed for G65 and R23 (Fig. 26B). 
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Fig. 26. Axonal colocalization of IE4, p65, and p23 after retrograde infection of DRG neurons. Axons of 
retrogradely infected DRG neurons in the middle of the channel were similarly (Fig. 25) live-monitored and pro-
tein-protein colocalizations were imaged by Keyence fluorescence microscope at 3 dpi (A) The first two images 
on the left side show the merged images of axons of G23-4R-infected DRG neurons followed by unmerged and 
merged magnification of the white-framed area from two independent observations. Arrowheads highlight a num-
ber of p23 (green) colocalization signals with IE4 (red). (B) Same axonal observation for axons of retrogradely 
G65-R23-infected DRG cells. Scale bar of the original image, 20 µm. 
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Although the colocalization patterns during anterograde and retrograde infections seemed to 
be absolutely identical, in the case of the retrograde infection we could not observe any fluo-
rescent signals until the infection had spread into the somal site and was detectable at ap-
proximately 2 dpi. At the same time, live tracking of the fluorescently tagged proteins in both 
directions did not detect movement at the times of observation, probably due to the late de-
tection of fluorescent viral particles. As a result, we could neither confirm nor deny the as-
sumption of a “married” or an “unmarried” model for the retrograde axonal transport of VZV in 
DRG cells. Nevertheless, it led us to the conclusion that the “married” model of VZV antero-
grade axonal transport is most likely during the course of infection in sensory neurons. 
4.4.3 Development of a novel adaptive compartmentalized neurons cultivation system 
Since we seeded the whole ganglion during VZV infection to study the axonal transport, we 
asked if the individual sensory neurons would give the same results. For this purpose, we 
developed a novel compartmentalized cultivation system based on that applied above. Using 
ibidi chemotaxis µ-slides 3D, dissociated sensory neurons were seeded into the proximal 
chamber and axons were allowed to grow through the agarose-filled channel for 1-2 weeks 
prior to the anterograde infection with cell-free G23-4R in the proximal chamber (Fig. 27A). 
After 2-3 h, medium was replaced with a virus-free medium and the infection was then obser-
ved under the Keyence fluorescence microscope as described for the first method. Similar 
colocalization signals of G23 and 4R within the infected sensory neurons axons in addition to 
infected somata were detected from 1-2 dpi and imaged at 3 dpi (Fig. 27B) showing results 
comparable to those of the ibidi µ-slides 60.4 (Fig. 25B). However, the new method was much 
faster and more efficient. Both the former and the later method were reliable and reproducib-
le according to the similar results from several independent experiments, further supporting 
our observations of “married” mode of axonal transport. 























Fig. 27: A novel compartmentalized cultivation system for the observation of axonal transport. (A) Disso-
ciated sensory neurons were seeded into the proximal chamber and axons were allowed to grow through a 0.1% 
agarose-filled channel toward the distal chamber for 1-2 weeks. Anterograde and retrograde infections at the 
proximal or the distal chamber, respectively, allowed tracing of the axonal colocalization of the fluorescence-tag-
ged VZV proteins. Infected neurons were live-monitored and protein-protein colocalizations were imaged by 
Keyence fluorescence microscope at 3 dpi. (B) The upper panel show the images of growing sensory neurons 
from the somata in the proximal chamber (far right) through the agarose-filled channel (two images in the middle) 
toward the distal chamber (far left). The lower panels represent G23, 4R, and merged images of the antero-
gradely G23-4R-infected sensory neurons showing the spread of infection to the somata and a similar colocali-
zation pattern of IE4 and p23 as observed above (Fig. 25B). Scale bars, 100 µm. 




5.1 Efficient en-passant mutagenesis of herpesvirus genomes in E. coli 
The development of the en-passant mutagenesis method by Tischer et al. in 2006 provided a 
highly efficient technique for the manipulation of bacterial artificial chromosome (BAC) con-
structs harboring infectious herpesvirus genomes. The VZV genome used in this study is 
maintained by a low-copy mini-F vector in the E. coli GS1783 strain. The mini-F cassette is 
located at the genomic terminal junction and released upon virus reconstitution and after 
three to four passages in permissive MeWo cells, resulting in an infectious virus without any 
foreign sequences. This system was developed by our research group by applying duplica-
ted viral sequences from both ends of the mini-F integration site that allowed the constant 
maintenance of the cloned herpesvirus genomes in the Red recombination-competent E. coli 
GS1783 strain. Therefore, these herpesvirus BACs can be repeatedly modified by the en-










3-4 passages in MeWovirus reconstitution
 
Fig. 28. Elimination strategy of the mini-F moiety. The mini-F cassette locates at the genomic terminal junction 
of a cloned-BAC genome of the wild-type isolate HJO of VZV (pHJOpac). Sequences of the mini-F plasmid are 
released upon reconstitution of pHJOpac in permissive MeWo cells and after three to four consecutive passages 
of the reconstituted virus (HJO). 
The en-passant mutagenesis was used for the generation of double fluorescently labeled 
VZV mutants with ORF-fluorescence fusions providing novel functions for VZV. In view of the 
retrograde axonal transport of the VZV small capsid protein p23 in comparison to its homo-
logs of HSV-1 and PrV (Antinone & Smith, 2010; Grigorian et al., 2012; Smith et al., 2001), 
we used a fluorescently labeled p23 in two viral double mutants as a VZV capsid control, in 
order to observe colocalizations with the tegument protein IE4 and also with the transmem-
brane envelope protein p65 within axons of VZV-infected embryonic Wistar rat DRG cells, in 




5.2 Recombinant viruses 
5.2.1 Replication-competence of recombinant viruses 
The open reading frame (708 bp) ORF23-encoded protein p23 is the smallest capsid protein 
of VZV according to its homology to the VP26/UL35 of HSV-1 that is known to be produced 
during the late phase of the virus replication cycle (Booy et al., 1994; McNabb & Courtney, 
1992). Besides p23, the products of ORFs 20, 33, 33.5, 40, and 41 form the VZV capsid. 
Based on the conserved functions among herpesviruses, the capsid proteins p20, p23, p40, 
and p41 form the outer layer of VZV capsid (Cohen et al., 1980; del Rio et al., 2005; Gibson 
& Roizman, 1972; Kut & Raschaert, 2004). Although the N-terminus of ORF23 conserves 
most of the amino acids of its herpesvirus homologs, its C-terminus has unique amino acid 
residues that characterize its nuclear localization capacity. Moreover, co-expression with 
ORF23 resulted in nuclear import of the major capsid protein of ORF40. Thus, an mRFP fu-
sion to the C-terminus of ORF23 resulted in a replication-incompetent virus in permissive 
melanoma cells suggesting incompatibility with capsid formation when mRFP is fused direct-
ly before the stop codon of ORF23 (Chaudhuri et al., 2008). Accordingly, only N-terminal 
fluorescent fusions of ORF23 were established by our group, which resulted in a replication-
competent virus upon reconstitution in permissive melanoma cells. 
VZV ORF4 (1359 bp) encodes an immediate early tegument protein (IE4) of VZV that is 
homologous to ICP27 (infected cell protein 27) of HSV-1. While the amino acids of both 
homologs show approximately 45% conserved sequences of which the C-terminal sequen-
ces are almost identical, IE4 could not functionally compensate for the loss of its homolog in 
an ICE27-null mutant of HSV-1. IE4 has transcriptional and posttranscriptional functions 
during all phases of the virus replication cycle and is known to be essential for the viral repli-
cation in vitro (Defechereux et al., 1993, 1997; Moriuchi et al., 1994; Perera et al., 1994; Sato 
et al., 2003). These transactivating properties are obtained during protein dimerization for 
which the central domain and the C-terminal cysteine-rich domain of ORF4 are important. 
These dimerization-important regions in addition to the arginine-rich domains Rb and Rc of 
the N-terminal region of ORF4 were also proved to be essential for the gene transactivation 
(Baudoux et al., 2000). Furthermore, IE4 has been found to function as a nucleocytoplasmic 
shuttling protein for the nuclear export of the viral mRNA. These shuttling properties are 
established by a nuclear localization signal identified within the Rb domain of the N-terminal 
region of ORF4 and a nuclear export mechanism partially depending on chromosome region 
maintenance 1 (CRM1). For the posttranscriptional function of ORF4, the nuclear localization 
signal was shown also to be indispensable (Baudoux et al., 2000; Huang et al., 2014; Ote et 
al., 2010). By our group, both C-terminal and N-terminal fusions of ORF4 and a fluorescent 
protein were conducted and yielded replication-competent viruses. However, in the case of a 
double fluorescence-tagged VZV genome, the cloned-BACs pG4R23 and pG23R4 were not 
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reconstitutable, whereas pG23-4R produced a replication-competent recombinant virus G23-
4R upon transfection into permissive melanoma MeMo cells. According to these results, it 
seems that a fluorescence fusion at the N-terminus of ORF4 or ORF23 was incompatible 
with the viral replication in a double fluorescence-labeled VZV. This could be a result of con-
formational changes in structures of both fluorescence-tagged viral proteins that interfered 
with transfection, reconstitution or replication in permissive MeWo cells. In the case of an 
established transfection, these structural changes could also block the viral genome entry or 
the virus egress from the cellular nucleus during the replication cycle, and could alternatively 
interfere with the previously described functional properties of the N-terminal regions of both 
viral proteins, which resulted in interference with the virus replication. On the other hand, an 
mRFP fusion to the C-terminus of ORF4 in a double fluorescence-tagged VZV genome 
retained the functional properties of both fluorescently tagged viral proteins IE4 and p23 in 
culture. 
The US region of the VZV genome encodes four ORFs. ORF65 (309 bp) is the smallest that 
encodes the transmembrane protein type II p65, which is known to be non-essential for the 
virus replication in vitro and for the infection of human skin and T-cells in vivo (Cohen et al., 
2001; Niizuma et al., 2003; Zhang et al., 2010). This protein is highly conserved among other 
α-herpesviruses such as the US9 proteins of the VZV close relatives HSV-1 and PrV (Cohen 
et al., 2001; Frame et al, 1986). In the VZV genome, the ORF65 gene differs from its US9 
homologs of HSV-1 and PrV in that it is dispensable for virus replication and it cannot replace 
the function of its homolog in a US9-null mutant of PrV (Cohen et al., 2001; Longnecker & 
Roizman, 1986; Mettenleiter et al, 1988). This protein has a hydrophobic C-terminus and 
20% serine and threonine residues in the N-terminal region and is phosphorylated by casein 
kinase II resulting in an apparent protein size of 16 kDa. According to the sequence of p65, 
the first 78 amino acids region is located in the cytoplasm, followed by an 18 amino acid 
region located in the membrane, and a 6 amino acid region forming the extracellular domain 
(Cohen et al., 2001; Davison & Scott, 1986). Since p65 is non-essential for virus replication, 
fluorescent protein fusions at the N-terminus and C-terminus of ORF65 were established by 
our group generating a replication-competent virus with a fluorescently expressed p65. For 
the double fluorescence-labeled viral recombinant G65R23, eGFP was fused to the intracel-
lular N-terminus of ORF65 expecting the eGFP moiety to be directed toward the cytosolic 
side upon virus reconstitution in permissive cells. Our results showed that both recombinant 
double color viruses G23-4R and G65R23 have replication kinetics similar to those of the 
wild-type HJO (Fig. 18). Moreover, a PCR analysis of the isolated viral DNA of G23-4R and 
G65R23 from infected melanoma cells in comparison to their intermediates G23 and G65 
confirmed the correct fusion sites (Fig. 19). Together, these results indicate the validity of the 
generated double fluorescence-labeled recombinant viruses for further analysis. 
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5.2.2 Verification of viral fusion gene expression 
First, the transcription of the fusion genes from the recombinant viruses G23-4R and 
G65R23 was monitored by detecting the viral mRNA from infected permissive MeWo cells 
via RT-PCR analysis. The results showed that all fusion transcripts were detectable and that 
the fusion sites were correct in comparison to the transcripts of the corresponding non-fusion 
genes from wild-type HJO-infected MeWo cells (Fig. 20). 
Second, the fusion proteins from lysates of G23-4R- and G65R23-infected MeWo cells were 
monitored by observing the related bands by immunoblot analysis using anti-GFP and anti-
RFP antibodies (Fig. 21). In previous studies, the capsid protein p23 showed a band of ap-
proximately 30-35 kDa, which is slightly higher than the calculated molecular size (24.4 kDa). 
This was suggested as a result of the phosphorylation of p23 at its 13 (six serine und seven 
threonine) possible phosphorylation sites (Chaudhuri et al., 2008; Lenac et al., 2013; Markus 
et al., 2011). In the present study, the G23 fusion protein was detected as expected at appro-
ximately 52-60 kDa, referring to the non-phosphorylated (24.4 kDa) and the phosphorylated 
(30-35 kDa) forms of p23 fused to 27 kDa of eGFP (Fig. 21, lane 3). A similar size was seen 
for the R23 fusion protein expression in addition to a very weak band at 27 kDa which may 
be related to a non-fused mRFP moiety (Fig. 21, lane 4). 
For the fluorescence-labeled immediate early fusion protein 4R, expression yielded a 78 kDa 
band due to a fusion of 27 kDa of mRFP to 51 kDa of IE4, in agreement with the calculated 
molecular weight of IE4 and also to previous observations (Davison & Scott, 1986; Lenac et 
al., 2013; Ng et al., 1994). In addition, our immunoblot of 4R showed another very weak 
signal at 27 kDa that might refer to an unfused mRFP moiey (Fig. 21, lane 3). 
Although the calculated molecular weight of the transmembrane protein p65 is 11 kDa 
(Davison & Scott, 1986), previous immunoblot analyses of p65 had exhibited a higher band 
at 16 kDa of the predicted p65-phosphorylated form (Cohen et al., 2001; Lenac et al., 2013; 
Niizuma et al., 2003). This phosphorylation was shown to be due to phosphorylation by 
casein kinase II at the serine and threonine residues sites located in the N-terminal half of 
p65 (Cohen et al., 2001). Our Western blot analysis of the fusion protein G65 showed a band 
at 38-40 kDa that is likely to relate to the 11 kDa of the p65-unphosphorylated form fused to 
27 kDa of eGFP (Fig. 21). 
As viral and cellular controls, anti-VZV-gI and anti-β-actin antibodies were applied illustrating 
expected bands at (53-100 kDa relating to the heterodimer gE/gI, Oliver et al., 2011) and 45 
kDa of β-actin (Fig. 21). In addition, MeWo cells infected with mRFP-expressing VZV and 
HeLa cells transfected with an expression vector of eGFP-β-actin fusion protein (72 kDa), 
were used to control the expression and the 27 kDa molecular weight of eGFP (Fig. 21, lane 
5) and mRFP (Fig. 21, lane 6). Lysates from uninfected cells did not show relevant viral or 
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fluorescent protein expression. Together, all fusion proteins were detectable at the expected 
molecular size via Western blot analysis. 
5.3 Cellular localization of viral proteins 
5.3.1 Intracellular localization in non-neuronal cells 
The intracellular distribution of p23, IE4, and p65 was examined at first in VZV-infected 
permissive MeWo melanoma and HFF fibroblast cells by confocal imaging at 2 dpi (Fig. 22, 
23). 
The capsid protein p23 is known to be expressed during the late phase of VZV replication 
cycle after infection. Since the viral capsid is assembled in the nucleus of infected cells, p23 
is predicted to localize mainly in the nucleus. Moreover, this protein was suggested to play a 
role in the nuclear transport of viral proteins during virus replication and also to be localized 
within the nuclear promyelocytic leukemia PML cages (Chaudhuri et al., 2008; Reichelt et al., 
2011). Consistently, our results showed that G23 and R23 proteins were detected within the 
nucleus with a strong expression and only weak punctuated signals were found in the 
cytoplasm of infected MeWo melanoma and HFF fibroblast cells (Fig. 22). 
As a transcriptional regulator protein, the VZV tegument IE4 is known to be expressed during 
the immediate-early or early phase of VZV replication cycle upon infection. While IE4 was 
suggested to localize in the nucleus during the early state of infection, it was predicted to 
translocate to the cytoplasm during ongoing infection (Cohen et al., 2005; Lungu et al., 1998; 
Ote et al., 2010). At 2 dpi, our results showed that the fusion protein 4R was distributed more 
often in the cytoplasm than in the nucleus of infected MeWo and fibroblast cells, which con-
cludes that at 2 dpi more cells have switched to the late state of infection (Fig. 22). 
As a late VZV transmembrane type II protein, p65 was suggested to localize to the mem-
brane and also to be distributed to TGN of infected permissive cells (Lyman et al., 2009). In 
the present study, the fusion protein G65 was detected on the surface of the infected cells 
and also in perinuclear structures of infected MeWo and HFF cells at 2 dpi, which turned to 
be at the distribution sites of the TGN marker golgin-97 (Fig. 22, 23). Together, these results 
were in agreement with previous data describing the distribution manners of the relevant viral 
proteins in VZV-infected non-neuronal cells (summarized in Tab. 6). 
5.3.2 Localization in neuronal cells 
The cellular distribution of p23, IE4, and p65 was also monitored in VZV-infected DRG-
derived sensory neurons from E18 rat embryos by confocal and fluorescent imaging at 2 dpi 
(Fig. 24). 
Similar to the distribution manners of the capsid protein p23 in non-neuronal cells, this 
protein was suggested to localize predominantly in the nucleus of infected neurons at 3-7 dpi 
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(Markus et al., 2011). Our results showed also that the G23 and R23 fusion proteins were 
localized mainly in the nucleus of infected sensory neurons with only weak punctuated sig-
nals in the cytoplasm. In contrast, the G65 fusion protein was only detectable in the cyto-
plasm of infected sensory neurons (Fig. 24). 
In the case of IE4, previous studies suggested that IE4 is present only in the cytoplasm in 
latently infected neurons, whereas its expression was distributed almost alike between the 
nucleus and cytoplasm upon reactivation (Gershon et al., 2008; Lungu et al., 1998). How-
ever, our results demonstrated that IE4 is predominantly but not exclusively in the cytoplasm 
of productively infected sensory neurons of E18 (Fig. 24), which is greatly consistent with its 
spreading patterns in non-neuronal cells discussed above. Together, these results were 
consistent with previous data defining the localization of the relevant viral proteins in VZV-
infected neuronal cells (summarized in Tab. 6). 
Tab. 6. Intracellular localization of IE4, p65, and p23 
Protein Localization in non-neuronal cells* Localization in neuronal cells** 
IE4 cytoplasm > nucleus cytoplasm >> nucleus 
p23 nucleus >>> cytoplasm nucleus >>> cytoplasm 
p65 TGN and membranes cytoplasm*** 
*described also in previous studies (Chaudhuri et al., 2008; Cohen et al., 2001, 2005; Lungu et al., 1998; Lyman 
et al., 2009; Ote et al., 2010; Reichelt et al., 2009, 2011). **described also in previous studies (Gershon et al., 
2008; Markus et al., 2011; Lungu et al., 1998). ***novel in this study. 
5.4 Axonal transport of VZV 
To investigate the axonal transport models of VZV, DRG neurons were infected with high 
titers of cell-free VZV using compartmentalized cultivation systems similar to those used ear-
lier to study the axonal transport of rabies virus (Bauer et al., 2014). Although it was shown 
that infecting the neuronal cells with cell-free VZV induced a latent (non-productive) infection 
(Gershon et al., 2008), a later study suggested that productive or non-productive infections of 
neuronal cells in culture are dependent upon the titers of the infectious cell-free preparations. 
While infection of neuronal cells with low titers of cell-free VZV resulted in a latent infection, 
high titers of infectious cell-free VZV induced a productive infection (Sluotskin et al., 2013). 
Based on that, productive infections of E18 sensory neurons were established by using high 
titers of infectious cell-free VZV of approximately 104-105 PFU/ml. 
5.4.1 Retrograde axonal transport of VZV 
During primary infection, α-herpesviruses are considered to reach the nuclei of DRG neurons 
by two mechanisms, either by the infected immune cells circulating in the blood vessels sur-
rounding the DRG sites or by fusion to the axonal membrane at the peripheral endings of the 
growth cones that innervate the infected peripheral tissues. Thus, the virus loses its envelop 
and most of the tegument proteins and the capsid is connected via the remaining tegument 
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proteins to the retrograde motor protein dynein (Diefenbach et al., 2008; Goldstein & Yang, 
2000; Ouwendijk et al. 2012; Smith, 2012). Dynein can also move anterogradely in a less 
effective way and can affect the overall transport velocity (Gross et al., 2000; Ross et al., 
2006; Smith, 2012). A kinetic analysis of the GFP-tagged VZV capsid protein p23 within 
axons of retrogradely VZV-infected neuronal cells showed that the movement of the viral 
capsid was detectable at 1 h post infection and turned to be discontinuous and bidirectional 
with a net retrograde motion which was at 6-10 h post infection significantly slower. At the 
late stage of infection, a high proportion of the observed viral capsids seemed to show a 
slower movement or to become stationary. This could be a result of the bidirectional trans-
port of dynein, the limited quantity of dynein available, and/or the decreased concentrations 
of adenosine triphosphate needed for axonal transport (Grigorian et al., 2012). Accordingly, 
we presume that the elongated forms of viral fluorescence signals detected from 2 dpi repre-
sent rather static clusters of several viral virions/particles remaining at the same position in 
the axons. Our results further showed that in axons of retrogradely infected DRG neurons, 
the capsid was almost exclusively colocalized with the tegument protein IE4 and with the 
transmembrane envelope protein p65. Separate punctuated red and green signals were 
rarely observed (Fig. 25, 26). However, shortly after infection and probably due to the limited 
resolution of our non-confocal fluorescence microscope, axonal protein signals could not be 
detected as previously described (Grigorian et al., 2012). Later on (from 2 dpi), the signals 
had spread into the somata indicating that the detected signals might result rather from ante-
rograde than of retrograde axonal transport (Fig. 26). In addition, axonal kinetics of the ob-
served viral proteins could not be observed which made it difficult to determine precisely the 
retrograde axonal transport type of VZV virions/particles. Therefore, the retrograde axonal 
transport model of VZV still needs further studies preferably by detecting the colocalization of 
the viral proteins immediately after infection with a much more sensitive microscopy tech-
nique. 
5.4.2 Anterograde axonal transport of VZV 
For the α-herpesviruses HSV-1 and PrV, there is the plausible consensus that the viral cap-
sid travels in retrograde direction without envelope using specific dynein-associated viral te-
gument proteins. In contrast, the anterograde axonal transport mechanisms seem to be more 
controversial leading to theories of two different axonal transport models called “married” and 
“unmarried” (separate) models. This results in the open question if the viral capsid travels 
with or without envelope in the axon (Diefenbach et al., 2008). Nevertheless, it was sugges-
ted that PrV capsids migrate according to the “married” model with envelope in anterograde 
axonal direction. Generally, a similar anterograde axonal transport model seems to be pro-
bable for HSV-1, assuming that both α-herpesviruses share the same axonal transport me-
chanisms (Diefenbach et al., 2008; Kratchmarov et al., 2012). In the present study, VZV p23 
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appeared to colocalize with 4R and p65 within axons of anterogradely infected DRG neurons 
(Fig. 25B, C) suggesting a simultaneous transport of IE4 and p65 with the VZV capsid. Con-
sequently, we strongly suggest that VZV capsids do not travel naked along axons of DRG 
neurons after reactivation of VZV, since IE4 is known to be part of the tegument and p65 is a 
transmembrane envelope protein of VZV (Cohen et al., 2001; Sato et al., 2003). As such, we 
prefer the “married” model of VZV anterograde axonal transport in DRG neurons, resembling 
that suggested for HSV-1 and PrV45. 
In anterograde infection of HSV-1 and PrV, the heterodimer transmembrane type I glycopro-
tein gE/gI and the transmembrane type I protein US9 are supposed to promote the antero-
grade transport of the virus particles from the neuronal cytoplasm into axons (Howard et al., 
2014; Johnson & Baines, 2011; Lyman et al., 2008; Miranda-Saksena et al., 2016). A signifi-
cant assembly defect of “married” virions in addition to the missorting of enveloped and non-
enveloped virus particles in the cytoplasm of infected neurons with gE-null and/or US9-null 
viral mutants resulted in a reduced anterograde transport of the virus particles. These defects 
suggest that gE/gI and US9 initiate assembly of enveloped particles in the cytoplasm and 
transport them into axons (DuRaine et al., 2017). So far, previous studies on the VZV gE/gI 
showed a role of the protein complex in the axonal spread of virus and viral proteins in DRG 
neurons (Christensen et al., 2011; Zerboni et al., 2007, 2011). Furthermore, our results 
showed that the US9 homolog of VZV p65 is a component of the trafficking virus particles 
along axons of DRG neurons after anterograde infection with VZV. However, it remains inte-
resting to examine whether p65 together with the VZV heterodimer gE/gI plays the same role 
in the anterograde axonal transport as that of the homologous proteins of the VZV close 
relatives HSV-1 and PrV. 
Based on these data, we approach another possible model for the anterograde axonal trans-
port of VZV in addition to the previously suggested “married model” (Fig. 29). By a “married 
model”, the VZV particles travel along the microtubules of the sensory neurons axons as 
completely assembled virions in anterograde direction (Fig. 29A). By an “alternative model”, 
capsids of incompletely assembled VZV virions migrate together with a portion of the tegu-
ment involving IE4 and a portion of the envelope involving the “axonal guidance” p65 and the 
heterodimer gE/gI (Fig. 29B). 
In culture, VZV replicates in a highly cell-associated manner and shows a narrow host range 
that limits the use of animal experiments. However, rats have been valuable as a behavioral 
model for VZV-induced allodynia and hyperalgesia (Fleetwood-Walker et al., 1999; Kress & 
Fickenscher, 2001). Sensory neurons from rat DRGs can be infected in cell culture with VZV 
showing signs of productive virus replication. Moreover, wild-type virus infected rat sensory 
neurons became sensitive to the pain-associated neurotransmitter noradrenalin, whereas 
this effect was almost absent when the cells were infected with the attenuated vaccine strain 
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Oka (Kress & Fickenscher, 2001; Schmidt et al., 2003). In the present study, we could also 
present embryonic Wistar rat DRG cells as valuable targets for the study of the axonal trans-
port of VZV. 
Taken together, the presented data establish that embryonic E18 rat DRG neurons are per-
missive to VZV and the applied compartmentalized cultivation systems are suited to further 
explore axonal transport mechanisms of VZV. Moreover, we emphasize the importance of 
IE4, a conserved protein among all α-herpesviruses, as a potential alternative antiviral target 
in addition to the non-essential “axonal guidance” protein p65. Thus, our results present 
models for the anterograde axonal transport of VZV and lead to further investigations into the 
axonal trafficking patterns of VZV in order to interfere with the pathogenesis of the neuro-
pathogenic and neuropathic functions of VZV. 
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Fig. 29: Scheme of VZV anterograde transport models. In this drawing, two models of the anterograde trans-
port of VZV particles are depicted within an axon of a sensory neuron. Somata of sensory neurons are clustered 
in the dorsal root ganglia (DRG) with axonal connections to the central nervous system (CNS) and to the skin. 
Retrograde axonal transport of cellular and viral particles occurs along the microtubules from the positive ends at 
the periphery to the negative ends at the somata (dashed light-red arrows); in contrast, anterograde axonal trans-
port takes place along the microtubules in an opposite direction from the negative ends at the somata to the posi-
tive ends at the periphery (dashed green arrows). (A) The drawing represents a “married model” of the antero-
grade axonal transport of a VZV virion by which the virus travels as a completely assembled enveloped virion. (B) 
The drawing represents an “alternative model” of the anterograde axonal transport of a VZV particle by which the 
capsid of an incompletely assembled virion migrates together with a portion of the tegument involving IE4 and a 
portion of the envelope involving the “axonal guidance” p65 and the heterodimer gE/gI. 
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6 MATERIALS AND METHODS 
6.1 Materials 
6.1.1 Plasmid, BACs, and viruses 
All BACs, plasmids, and reconstituted viruses that have been used or constructed during this 
study are listed below (Tab. 7). The generated virus strains are maintained within infected 
MeWo cells, since VZV is a cell-associated virus. 
Tab. 7. Plasmids, bacterial artificial chromosomes, and recombinant varicella zoster viruses 
Variable Feature Reference 
Plasmids   
pEP-EGFP-in transfer vector of the positive selection marker gene 
(KanR) with eGFP sequences and an I-SceI recognition 
site 
Tischer et al., 2006 
pEP-mRFP1-in transfer vector of the positive selection marker gene 
(KanR) with mRFP sequences and an I-SceI recognition 
site 
Tischer et al., 2006 
Bacterial artificial chromosomes (BACs)  
pHJO genome of the European wild-type isolate HJO of VZV in-
cluding the mini-F cassette located at the genomic ter-
minal junction 
Wussow et al., 2009 
pG4 pHJO with eGFP fused to the N-terminus of ORF4 Spieckermann, 2013 
pG4R23 pG4 with mRFP fused to the N-terminus of ORF23  
pG23 pHJO with eGFP fused to the N-terminus of ORF23 Spieckermann, 2013 
pG23R4 pG23 with mRFP fused to the N-terminus of ORF4  
pG23-4R pG23 with mRFP fused to the C-terminus of ORF4  
pG65 pHJO with eGFP fused to the N-terminus of ORF65 Spieckermann, 2013 
pG65R23 pG65 with mRFP fused to the N-terminus of ORF23 Spieckermann, 2013 
Viruses  
HJO pHJO without the mini-F cassette upon reconstitution and 
passaging in melanoma MeWo cells 
Wussow et al., 2009 
G23 pG23 without the mini-F cassette upon reconstitution and 
passaging in melanoma MeWo cells 
Spieckermann, 2013 
G23-4R pG23-4R without the mini-F cassette upon reconstitution 
and passaging in melanoma MeWo cells 
 
G65 pG65 without the mini-F cassette upon reconstitution and 
passaging in melanoma MeWo cells 
Spieckermann, 2013 
G65R23 pG65R23 without the mini-F cassette upon reconstitution 
and passaging in melanoma MeWo cells 
Spieckermann, 2013 
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6.1.2 Buffers and chemicals 











30% acrylamide mix 
1.5 M Tris (pH 8.8) 
10% (w/v) sodium dodecyl sulfate (SDS) 
10% (w/v) ammonium persulfate (APS) 
Tetramethylethylenediamine (TEMED) 
Stacking gel 








30% acrylamide mix 










1x transfer buffer 10 ml 
10 ml 
80 ml 
10x SDS running buffer 
methanol 
water 




0.1 % (w/v) 
Tris-HCl (pH 6.8) 
SDS 
glycerol (Gerbu, Heidelberg) 
2-mercaptoethanol (freshly added) 
bromophenol blue in water 
Radioimmunoprecipita- 







Tris-HCl (pH 7.5) 
NaCl 
ethylenediaminetetraacetic acid (EDTA, pH 8) 
Igepal CA-630 (Nonidet P-40) 
SDS 
Na deoxycholate 
RIPA-PIC buffer 50 ml 
1 tablet 
RIPA buffer 
proteinase inhibitor cocktail (PIC) 
TBST buffer 
(Tris buffered saline with 





Tris (pH 7.5) 
NaCl 
WB blocking buffer 5% (w/v) non-fat dried milk in TBST buffer 
WB stripping buffer 








Tris-HCl (pH 7.5) 
All chemicals presented were obtained from the following companies, Sigma-Aldrich (Tauf-
kirchen), Roth (Karlsruhe) or Merck (Darmstadt). Exceptions are specifically mentioned. The 
water used is distilled, sterile water, when nothing else is mentioned. 
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Tab. 9. Buffers for the agarose gel electrophoresis 
Component Composition 







EDTA (pH 8) 
Agarose gel 0.6-1.0% agarose (Life technologies, Darmstadt) in 1x TBE and 5:100,000 
ethidium bromide 




EDTA (pH 8) 
bromophenol blue in water 
Tab. 10. Buffers for the DNA-analysis 
Buffer Composition 
Buffer I 10 mM 
25 mM 
100 µg/ml 
EDTA, pH 8 
Tris-HCl, pH 8 
RNase A (Thermo Scientific)  
Buffer II 0.2 M 
1% (v/v) 
Na hydroxide (NaOH)  
Na dodecyl sulfate (SDS) 
Buffer III 3 M K acetate, pH 5.5 





proteinase K (Roche); in water 
6.1.3 Media and reagents 









NaCl (pH 7) 








agarose in LB-medium 
kanamycin (in water) 
chloramphenicol (in ethanol) 
ampicillin (in water) 
Tab. 12. Cell culture reagents and media 
Variable concentration Manufacturer 
Cell culture (virus)   
Dulbecco modified Eagle's minimal 
essential medium (DMEM) without L-
glutamine (“high glucose”) 
4.5 g/l glucose Biochrom (Berlin) 
DMEM with L-glutamine (“low lucose”) 1 g/l glucose Biochrom 
Fetal bovine serum (FBS) - PAA (Cölbe) 
L-glutamine (100x) 200 mM Biochrom 
OptiMEM (improved minimal essential 
medium MEM) 
- Life technologies 
PBS (Phosphate buffered saline) without 
Ca2+ und Mg2+ 
- Biochrom 
Penicillin/streptomycin (P/S, 100X) 10,000 U/ml or 10 mg/ml 
U = units 
Biochrom 
10x trypsin (1:250)/EDTA  0.5% trypsin, 0.2% EDTA Biochrom 
Trypsin 2.5% in PBS - Biochrom 
Lipofectamine 2000 - Thermo Scientific (Darmstadt) 
Trypan blue - Biochrom 
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Variable concentration Manufacturer 
Cell culture (DRG)   
Hank’s balanced sault solution (HBSS) - Gibco 
Neurobasal medium NBM (21103-049) - Gibco 
B-27-supplement (50x) serum free 
(protein-lipid complex) 
- Gibco 
GlutaMAX supplement (100x) 200 mM L-alanyl-L-glutamine-
dipeptide in 0.85 % NaCl 
solution 
Gibco 
Nerve growth factor (NGF 2.5S native 
mouse protein) 
- Invitrogen 
Defined trypsin inhibitor 1x (DTI) - Gibco 
Cytosine β-D-arabinofuranoside hydro-
chloride (cytosine arabinoside, Ara-C) 
- Sigma-Aldrich 
Poly-L-lysine hydrobromide (70-150 MDa) - Sigma-Aldrich 
Laminin - Sigma-Aldrich 
Nerve growth factor (NGF 2.5S native 
mouse protein) 
- Invitrogen 
Tab. 13. Used cell culture media and solutions 
Variable Composition 
D10  DMEM „high glucose”, 10% (v/v) FBS, 100 U/ml or 100 μg/ml P/S, 
2 mM L-glutamine 
supplemented NBM NBM, 100 U/ml P/S, B-27 0.02% (v/v), 0.5-2 mM GlutaMAX, 12.5 
ng/ml NGF 
Freezing medium FBS 10% (v/v) in dimethyl sulfoxide  (DMSO, Biomol, Hamburg) 
10% (v/v) FBS FBS in 1x PBS 
4% paraformaldehyde 4% paraformaldehyde in 1x PBS, pH 7.2 
Saponin saponin in 1x PBS 
Sucrose-glutamate-serum buffer (PSGC) 
buffer 
5% (w/v) sucrose, 0.1% (w/v) Na-glutamate, 10% (v/v) 
FBS in 1x PBS (freshly added) 
Zamboni’s fixative buffer 2% (w/v) paraformaldehyde, 15% (v/v) saturated 1.2% picric acid in 
0.1 M phosphate buffer, pH 7.3 
Tab. 14. PCR reagents 
Variable Reagents Manufacturer 
 dNTPs (10 mM) Thermo Scientific 
PCR with Taq DNA-polymerase  10x Taq-buffer 
MgCl2 (25 mM) 
10x (NH4)2 SO4 
Taq polymerase (1 U/µl) 
Thermo Scientific  
Thermo Scientific  
Thermo Scientific  
Thermo Scientific 
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6.1.4 Oligonucleotides 
Oligonucleotides were manufactured by Biomers (Ulm). 
Tab. 15. Primers (for, forward orientation; rev, reverse orientation) 
Code Description Sequence (5´3´) 
1) en-passant mutagenesis 
2232 eGFP-23 for GTG GTG GGG TTG CTG GGA TCA AAG ACT ACA CGA GAC GAT GCG 
GGT TGT GTC TTG TAC AGC TCG TCC ATG C 
2233 eGFP-23 rev CGC AGA TGT ACG TGT ATG CTG TTA TCG ATT GTC CCG TAA ACT 
AAT AAA CGA TGG TGA GCA AGG GCG AGG A 
3077 4-mRFP for ATA CAA ATT AGT ATG TTT TGA CAA GCA TGA AAA AGG TAT TTT 
TTA TTT TAC AAG GCG CCG GTG GAG TGG C 
3078 4-mRFP rev CTG ACG CCC GTC CAT ACG GTA AAT ATT TTA AGT GTA GTA CCT 
TTA ACT GCG CCT CCT CCG AGG ACG TCA T 
2409 eGFP-65 for GGT ATT AAA CAC TTT TAA ACT AGC CTG CTG GCC TTA CAA TCT 
GGA TTT CTA TGG TGA GCA AGG GCG AGG A 
2410 eGFP-65 rev GCT TCC ATC AGT AAG GCC ACG GCC TCA CCC TCC ATG GTG TTT 
TGT CCG GCC TTG TAC AGC TCG TCC ATG C 
2559 mRFP-23 for GTG GTG GGG TTG CTG GGA TCA AAG ACT ACA CGA GAC GAT GCG 
GGT TGT GTC AAG GCG CCG GTG GAG TGG C 
2560 mRFP-23 rev CGC AGA TGT ACG TGT ATG CTG TTA TCG ATT GTC CCG TAA ACT 
AAT AAA CGA TGG CCT CCT CCG AGG ACG T 
3075 mRFP-4 for TCT TCA CAA ATA GTA GAC ACG TCT GGG TCG GTT GGA ATT GAA 
GCA GAG GCC AAG GCG CCG GTG GAG TGG C 
3076 mRFP-4 rev CGG AAG ATA CAG GCA ACT GCA AAC ACG CAA TTG TCA GAT ATT 
TTG CAG CCA TGG CCT CCT CCG AGG ACG T 
2) PCR-primers 
1836 eGFP-23 for AGC AAG GGC GAG GAG CTG TTC 
1521 eGFP-23 rev TTC TGG CAT CAG CGA TGT C 
1549 ORF-23 rev GAC ATA TGC CCT GTT CGT TG 
925 ORF4 rev ATA TAT CCC CAA CGT CGC C 
2368 ORF4 for AAT GCA AAG TCA TCC GAA GG 
2369 ORF4 rev TGA CTA AAC ACG CCC ATT GC 
1158 4-mRFP for GCG TGA GAG AGT CAT ACG TGG 
3210 4-mRFP rev TTG GTC ACC TTC AGC TTG GC 
1836 eGFP-65 for AGC AAG GGC GAG GAG CTG TTC 
1527 eGFP-65 rev CTC CCG TCA TAG CAA ATA C 
1578 mRFP-23 for CGA CAT CAA GCT GGA CAT C 
1521 mRFP-23 rev TTC TGG CAT CAG CGA TGT C 
3211 GAPDH for GCA GGG GGG AGC CAA AAG GG 
3212 GAPDH rev TGC CAG CCC CAG CGT CAA AG 
6.1.5 Restriction enzymes 
All used restriction enzymes were manufactured by Thermo Scientific. 
Tab. 16. Restriction enzymes 
Enzyme Recognition sequence 
XhoI 5’ …C▼T C G A G… 3’ 
3’ …G A G C T▲C… 5’ 
BglII 5’ …A▼G A T C T… 3’  
3’ …T C T A G▲A… 5’ 
HindIII  5’ …A▼A G C T T… 3’ 
3’ …T T C G A▲A… 5’ 
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6.1.6 Antibodies 
Tab. 17. Antibodies and their origin, application, dilution, and manufacturer 
Antibody Species, application, dilution Manufacturer 
primary antibody   
Anti-VZV glycoprotein I, VZV-gI, 
monoclonal 
mouse, immunofluorescence, 1:1000 Merck Millipore (Darmstadt) 
Golgin 97 (monoclonal) mouse, immunofluorescence, 1:200 Santa Cruz (Heidelberg) 
ß-III-Tubulin (monoclonal) mouse, immunofluorescence, 1:50-
1:200 
Invitrogen 
Anti-GFP (polyclonal) rabbit, immunoblot, 1:1000 Invitrogen 
Anti-RFP (monoclonal) mouse, immunoblot, 1:750 Abcam (Cambridge, UK) 
ß-Actin (monoclonal) mouse, immunoblot, 1:1000 CellSignaling (Leiden, Netherlands) 
secondary antibody   
Alexa Fluor-488-conjugated, goat 
anti-mouse, polyclonal 
goat, immunofluorescence, 1:1000 Invitrogen 
Alexa Fluor-568-conjugated, goat 
anti-mouse, polyclonal 
goat, immunofluorescence, 1:1000 Invitrogen 
Alexa Fluor-350-conjugated, anti-
mouse, polyclonal 








goat, immunoblot, 1:3000 CellSignaling 
6.1.7 Cell culture materials 
The materials were obtained from the mentioned manufacturers (Tab. 18). 
Tab. 18. Used materials 
Material Manufacturer 
Culture slides Hartenstein (Würzburg) 
Cover slips 5-8 mm Hartenstein 
Cell culture flasks Greiner bio-one 
Cell culture multi-well plates Greiner bio-one (Frickenhausen) 
Cell culture pipettes Greiner bio-one 
Cell culture pipettes 25 ml Sarstedt (Nümbrecht) 
Conical screw cap tubes 15 ml Sarstedt 
Conical screw cap tubes 50 ml Greiner 
Cryo screw cap tubes Greiner 
Cuvettes for electroporation Bio-rad (München) 
Erlenmeyer flasks Schott 
Filter-pipette tips Sarstedt 
PCR tubes Biozym Scientific (Hessisch Oldendorf) 
Pipette tips Sarstedt 
Reaction tubes Sarstedt 
Round filter Hartenstein 
Spatulas and spoons Aesculap (Tuttlingen) 
Sterile filter 0.45 μm und 0.22 μm VWR (Darmstadt) 
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6.1.8 Equipment 
The following equipment were obtained from the manufacturers mentioned below (Tab. 19).  
Tab. 19. Equipment 
Equipment Manufacturer 
32°C incubator Binder 
-80°C freezer Heraeus 
Amaxa Nucleofector Lonza (Basel, Switzerland) 
Bunsen burner Camping Gaz 
CO2-incubator HeraCell 240 Hereaus/Thermo Scientific 
Cryo freezing Container Nalgene/Thermo Scientific 
Electrophoresis PowerSupply EPS301 GE Healthcare (Freiburg) 
Fluorescence microscope BZ-9000 Keyence (Osaka, Japan) 
Fluorescence microscope IX81 Olympus (Tokyo, Japan) 
Freezer Liebherr 
Gel chambers PeqLab 
Gel iX imager Intas (Göttingen) 
Gene Pulser XCell BioRad (München) 
Heat-magnetic stirrer COMBIMAG RET IKA (Staufen) 
Image system LAS-300 (CCD-Kamera) Fuji (Tokyo, Japan) 
inverted microscope DM IL Leica (Wetzlar) 
Laser scanning confocal microscope 510 Zeiss (Oberkochen) 
Laser scanning confocal microscope FV1000 Olympus (Tokyo, Japan) 
Micro scale BP 210 S Sartorius (Göttingen) 
Multifuge 4KR  Hereaus, Thermo Scientific 
NanoDrop 2000/2000c PeqLab 
pH-meter SevenEasy Mettler Toledo (Gießen) 
Photometer Eppendorf (Wesseling-Berzdorf) 
Pipetteboy Integra 
Refrigerator Liebherr 
Roller/Mixer Smart SRT9 BioCote (Wolverhampton, UK) 
Scale EG Kern (Balingen) 
SDS-electrophoresis-chambers dual gel caster GE Healthcare 
Semi-dry blot-device TransBlot SD BioRad (München) 
Shaker-incubator HT Multitron Infors (Basel, Schweiz) 
Shaker Rotamax 120 Heidolph 
Sonifier 250 Branson (Danbury, USA) 
Stage top heater (for the Keyence microscope) TOKAI HIT (Fujinomiya-shi, Shizuoka, Japan) 
Sterile hood (Laminar Flow) HeraSafe  Heraeus, Thermo Scientific 
Table-top centrifuge 5804 R Eppendorf 
Table-top centrifuge Pico/Fresco  Heraeus/Thermo Scientific 
Thermo cycler T3000 Biometra (Göttingen) 
Thermo mixer compact Eppendorf 
Ultrasonic bath Brandelin (Berlin) 
Vacuum pump system Vacuubrand 
Vortex Genius 3 IKA 
Water bath Memmert (Schwabach) 
Water bath Grant GLS 400 VWR (Darmstadt) 
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6.2 Molecular biology methods 
6.2.1 Plasmid-DNA preparation 
The isolation of plasmids and BACs from E. coli for analysis and cloning purposes were 
performed by alkaline lysis (Birnboim & Doly, 1979). Bacteria harboring the constructs were 
grown overnight in 7 ml LB medium with the corresponding antibiotics (30 μg/ml Cm, 35 
μg/ml Kan, and/or 100 μg/ml Amp) at 32°C (GS1783) or 37°C (XL-1 Blue) and 220 rounds 
per minute (rpm) until the stationary phase was reached and then pelleted by centrifugation 
at 3,500 rpm for 10 min (75006475-rotor, Heraeus). The pellet was resuspended in 300 μl of 
ice-cold buffer I (Tab. 10) with RNAse A for bacterial RNA degradation. For bacterial lysis, 
300 μl of buffer II at room temperature (Tab. 10) were added to the suspension and the 
mixture was incubated for 3-5 min at room temperature. Immediately, 300 μl of ice-cold 
buffer III (Tab. 10) were added to the mixture and the resulting solution was incubated on ice 
for 10 min. At room temperature, the genomic DNA and cell debris were sedimented by 
centrifugation of the mixture at 13,000 rpm for 15 min (75003424-rotor, Thermo Scientific) 
and the supernatant was then mixed with 600 μl isopropanol. The plasmid DNA was 
precipitated in isopropanol and pelleted at 13,000 rpm for at least 30 min (75003424-rotor). 
The plasmid DNA was washed with 800 μl 70% ethanol, pelleted again at 13,000 rpm for 10 
min (75003424-rotor). Finally, the ethanol residues were allowed to evaporate and the pellet 
was allowed to dissolve in 50 µl water for approximately 30 min at room temperature. For 
further experiments, the isolated plasmid DNA was stored at -20°C, BAC-DNA at 4°C. The 
prepared DNA was used for PCR analysis, RFLP analysis, and cloning purposes. BAC DNA 
for transfection into permissive MeWo cells was prepared with the Plasmid Maxi Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. The purified DNA was 
allowed to dissolve in 100 μl water and was stored at 4°C. The DNA concentration was then 
measured via Nano-Drop at 1 OD = 50 µg/µl. 
6.2.2 Polymerase chain reaction 
DNA amplification via PCR serves as analytical procedure for DNA fragments analysis, pre-
paration for cloning, recombination, and DNA sequencing. For the DNA fragments analysis, 
Taq DNA-polymerase was used (Tab. 14). Usually, plasmids and BAC DNA served as matri-
ces for PCR analysis. However, for the colony PCR, cell material was directly picked from 
the grown colonies and resuspended in the PCR solution (25-50 µl). In order to identify the 
positive colonies, all picked colonies were separately grown onto selective agar plates. 
The PCR program started with an initial denaturation at 95°C for 5 min. Afterwards, 35 cycles 
were applied consisting of a denaturation at 95°C for 30 s, an annealing of the oligonucleo-
tides at 55°C for 30 s, and an elongation of the DNA fragment with Taq DNA-polymerase at 
72°C for 1 min/kb. The final elongation step was achieved at 72°C for 10 min followed, when 
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necessary, by a hold time at 4°C. The PCR products were then stored at -20°C for further 
experiments. 
For the preparation of larger DNA fragments with homologous sequences (e.g., primers used 
for the en-passant mutagenesis), HotStar DNA-polymerase (Tab. 14) was used to avoid self-
annealing of the homologous sequences of the used primers. In this case, the PCR program 
started with an initial denaturation at 95°C for 15 min. Subsequently, 35 cycles were applied 
consisting of a denaturation at 95°C for 30 s, an annealing of the oligonucleotides at 55°C for 
30 s, and an elongation of the DNA fragment with the HotStar DNA-Polymerase at 72°C for 1 
min/kb. The final elongation step was achieved at 72°C for 10 min followed, when necessary, 
by a hold time at 4°C. The PCR products were then stored at -20°C for further experiments. 
The Phusion High-Fidelity DNA-Polymerase is used for critical applications such as cloning 
purposes, since the very low error rate of this polymerase is determined to 4.4 x 10-7. Accor-
dingly, the PCR procedure was performed following the manufacturer’s instructions. 
For PCR analysis of the viral DNA, permissive melanoma MeWo cells were first infected with 
300-400 PFU/ml of the virus in a 6-well dish. After 4 d of infection, the infected MeWo cells 
were harvested with 10 ml D10 medium and pelleted at 1200 rpm for 10 min (A-4-44-rotor, 
Eppendorf). The pellet was then resuspended in 200 µl lysis buffer (Tab. 10) and incubated 
at 56°C for 1-2 h for the degradation of all cellular and viral proteins by proteinase K. In order 
to prevent the proteinase K from digesting the DNA polymerase during the PCR, the 
proteinase K was then inactivated for 10 min at 95°C. Similarly, the PCR constructs were 
stored at -20°C. 
The resulting PCR products were analyzed electrophoretically by a 1% agarose gel, visuali-
zed by ethidium bromide staining, and the desired PCR fragments were, as necessary, ex-
tracted from the gel and purified with the NucleoSpin Extract II kit (Macherey-Nagel, Düren). 
The purified DNA fragments were applicable for electroporation or for sequencing. 
6.2.3 Restriction fragment length polymorphisms 
The integrity of the BAC DNA was analyzed for expected restriction fragment length polymor-
phisms (RFLP). For every RFLP analysis of the generated BAC DNA, 1 μl of the desired re-
striction enzyme (0.3-0.5 U/μl) was used per 20 μl digestion solution including 2 µl 10x enzy-
me buffer and 15 µl of the mini-prepared BAC DNA. The digestion was performed at required 
temperatures according to the manufacturer’s instructions (New England Biolabs or Thermo 
Scientific), mostly overnight (approximately 16 h) at 37°C. The digested BAC DNA was then 
analyzed electrophoretically by a 0.6% agarose gel resulting in different explicit DNA frag-
ment patterns that were identified in comparison with those of reference data via the Vector 
NTI software (Life technologies). 
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6.2.4 Agarose gel electrophoresis 
The agarose gel electrophoresis serves for the separation of the DNA fragments according to 
their sizes. The DNA fragments resuspended in the loading buffer were visualized by ethi-
dium bromide staining under ultraviolet light. The agarose gel was used in different concen-
trations according to the size of the DNA fragments. The low concentration (0.6%) agarose 
gel is used for large DNA fragments, whereas the high concentration (1.0%) agarose gel is 
more appropriate for small DNA fragments. The DNA was separated at 120 V and 400 mA in 
1 h. In contrast, the digested BAC DNA constructs were separated electrophoretically over-
night via a 0.6% (w/v) agarose gel at 50 V and 400 mA. The visualization and detection of 
the DNA fragments were achieved via the gel documentation software Gel iX imager (Intas, 
Göttingen) and then represented as inverted images. 
6.2.5 Electrocompetent bacteria preparation 
In order to prepare the bacteria (E. coli GS1783 strain) for the transfection with the PCR 
product of interest, the bacteria were subjected to several treatment steps. First, an overnight 
culture containing the corresponding clone was incubated in 10 ml LB medium with Cm at 
32°C and 220 rpm. The next day, the overnight cell culture was inoculated 1:20 in 50 ml LB 
medium with Cm. This main culture was then incubated at 32°C and 220 rpm until it reached 
an optical density (OD600) of 0.5-0.7. In order to induce the expression of the Red-protein 
genes exo, beta, and gam needed for the recombination steps, the culture was incubated in 
a 42°C water bath and at 220 rpm for 15 min. Subsequently, the culture was transferred to 
an ice-water bath for 20 min and 220 rpm. After centrifugation of the culture at 4,500 x g and 
0°C for 5 min, the bacterial sediment was washed three times with 50 ml ice-cold 10% (v/v) 
glycerol in distilled water und finally resuspended in 500 µl of 10% glycerol (1:100 of the 
original culture volume). At last, the suspension was portioned into 50 µl samples and shock-
frozen in a dry ice ethanol bath then stored at -80°C. 
6.2.6 En-passant mutagenesis 
The Red-recombination steps were performed via the en-passant mutagenesis technique in 
the E. coli GS1783 strain which is a derivative of the DY380 strain. The expression cassette 
of the Red-recombination proteins exo, beta, and gam is regulated by a temperature sensi-
tive promoter on a defective λ-prophage integrated within the bacterial genome. Furthermore, 
the GS1783 strain includes the endonuclease I-SceI gene (Aph AI) whose expression is in-
ducible by L(+)-arabinose (Lee et al., 2001; Tischer et al., 2006). 
First, the en-passant PCR product was amplified with the HotStar DNA polymerase using the 
corresponding oligonucleotides. This PCR product is needed for the first Red-recombination 
step and it is composed of the positive selection marker (KanR), eGFP or mRFP sequences, 
and the I-SceI recognition site. The PCR product was analyzed on a 1% (w/v) agarose gel 
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and purified. A portion (100 ng) of the purified PCR product were electroporated into the 
electrocompetent bacteria in 1 mm cuvettes at 1500 V, 25 µF, and 200 Ω. Immediately after 
the second pulse, the bacteria were mixed with 1 ml LB medium (without antibiotics) and 
then incubated at 32°C and 350 rpm for 2 h. After the recombination through the homologous 
50 bp sequences of the PCR product, the positive colonies were selected on Petri dishes 
with selective agar containing Cm and Kan, since the positive colonies were resistant against 
Cm and Kan after the first Red-recombination step. 
In order to generate a seamless fusion mutant, the kanamycin cassette was excluded from 
the BAC-cloned genome via a second Red-recombination step. First, an over-night culture of 
the bacteria from the first Red-recombination was inoculated in 5 ml LB medium containing 
Kan and Cm. The next day, 100 µl of the overnight culture were inoculated in 2 ml LB medi-
um containing just Cm and then incubated at 32°C and 220 rpm. After 3-4 h, a mixture of 2 
ml LB medium containing Cm and 1% (w/v) L(+) arabinose was added to the culture and 
incubated again at 32°C and 220 rpm for 60 min. This step is applied in order to induce the 
expression of the endonuclease I-SceI gene that cleaves the genome at the I-SceI recogni-
tion site resulting in a double strand cleavage close to the Kan cassette. Subsequently, the 
Red-proteins genes were induced at 42°C and 220 for 30 min for the following Red-recombi-
nation of the homologous duplications at the cleavage site. The bacteria were then incubated 
for another 4 h at 32°C and 220 rpm and finally plated in different dilutions (10-4 - 10-6) onto 
LB-agar plates containing Cm and 1% (w/v) L(+) arabinose for 2 d. The positive colonies 
were then, as mentioned before, detected by colony PCR, identified by RFLP analysis, and 
finally verified by sequencing the flanking areas of the fusion sites. 
6.2.7 Sequencing 
For the DNA sequencing of BAC and plasmid DNA after cloning or recombination processes, 
the Sanger sequencing method using chain-terminating inhibitors was applied (Sanger et al., 
1977). Accordingly, 50-100 ng of the purified DNA fragment were used. The entire sequen-
cing solution of 10 µl was composed of 1/10 BigDye Version 1.1 (Applied Biosystems, Darm-
stadt), 0.5x sequencing buffer, and 0.5 μM of the corresponding oligonucleotides. The se-
quencing program started with an initial denaturation at 96°C for 1 min. Afterwards, 24 cycles 
were applied consisting of a denaturation at 96°C for 10 s, an annealing of the oligonucleo-
tides at 50°C for 5 s, and an elongation of the DNA fragment at 60°C for 4 min. The samples 
were then sequenced on a capillary sequencer (DNA Analyser 3700, Applied Biosystems, 
Darmstadt) in the Institute for Clinical Molecular Biology of Kiel University. Finally, the se-
quencing data were analyzed by the Vector NTI software (Life technologies). 
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6.2.8 RNA isolation and reverse transcriptase PCR 
RNA was extracted from infected cells according to a published protocol (Chomczynski & 
Sacchi, 1987). VZV-infected MeWo cells were scraped from a T75 cell culture flask at 3-4 dpi 
in 4 ml ice-cold PBS. Infected cell suspension was then centrifuged at 1200 rpm and 4°C for 
10-15 min (A-4-44-rotor). After discarding the supernatant, the pellet were shock-frozen and 
stored at -80°C until needed for further experiments. For RNA isolation, the pellet was 
resuspended in 1 ml Trizol reagent (Invitrogen, Darmstadt, Germany) and incubated at room 
temperature for 5 min. Hereafter, 200 µl chloroform (Fluka, Merck, Darmstadt, Germany) 
were added and the suspension was shaken for 15 s before incubating again at room 
temperature for 2-3 min. For the phase separation, the mixture was centrifuged for 15 min at 
13,000 rpm and 4°C (75003424-rotor). The RNA-containing aqueous phase was then 
isolated and collected in 500 µl isopropanol for RNA precipitation. After incubation for 10 min 
at room temperature, RNA was sedimented by centrifugation at 13,000 rpm and 4°C for 15 
min (75003424-rotor). RNA-sediment was then washed in 1 ml 70% ethanol by centrifugation 
at 8,000 rpm and 4°C for 10 min (75003424-rotor) and ethanol was allowed to evaporate 
before dissolving the RNA-sediment in 30 µl ice-cold PCR-water (5 PRIME, Hilden). The 
RNA concentration was then measured via Nano-Drop at 1 OD = 40 µg/µl. Thereafter, 16 µg 
RNA were treated with 5 U DNase I (10 U/μl; Roche), 1x DNase buffer (5 µl), and 20 U 
RNase-inhibitor (Thermo Scientific) in a total volume of 50 µl for 20 min at 37°C to degrade 
residual genomic DNA. Finally, DNase I was deactivated upon incubation at 75°C for 10 min 
and the RNA was then stored, when needed, at -80°C. 
For the complementary cDNA synthesis, 1 µg (2 µl) oligo (dT)12-18 primer (Invitrogen) and 
500 µM (2 µl) dNTPs (Thermo Scientific) were added to 25 µl DNase-I-treated RNA, then 
incubated at 65°C for 5 min before cooling on ice. The mixture was then supplemented with 
5x transcription buffer (8 µl) and 5 mM (2 µl) dithiothreitol (DTT, Thermo Scientific), then 
incubated at 42°C for 2 min. Subsequently, 200 U (1 µl) superscript II RT (Invitrogen) were 
added for the cDNA synthesis upon incubation at 42°C for 15 min before RT deactivation at 
70°C for 15 min. In parallel, negative-control samples were prepared without RT supplement, 
in order to confirm the absence of cellular and viral DNA contaminations. 
For the RT-PCR analysis, the viral fusion genes sequences were amplified from total cellular 
cDNA mix with phusion polymerase. As a positive cellular reference, glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) transcripts were detected in all samples to confirm the cor-
rect cDNA synthesis. As a negative control, fusion genes were detected in RNA isolates from 
wild-type HJO-infected MeWo cells. In a total volume of 20 µl, 2 µl cDNA, 1x (4 µl) HF buffer, 
200 µM (0.4 µl) dNTPs, 0.5 µM (0.2 µl) of each forward and reverse oligonucleotide (Tab. 
20), and 0.4 U (0.2 µl) phusion polymerase were mixed for RT-PCR analysis. All melting 
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temperatures of the used oligonucleotides were calculated via the TM calculator of Thermo- 
Fisher (www.finnzymes.com/tm_determination.html) as summarized in Tab. 20. 
Tab. 20. Melting temperatures of RT-PCR oligonucleotides and annealing temperatures of the fusion genes 
Code Oligonucleotide Melting temperature Annealing temperature 
1836 eGFP-23 for 71.2°C 
68.6°C 
1521 eGFP-23 rev 65.6°C 
1158 4-mRFP for 65.2°C 
68.2°C 
3210 4-mRFP rev 67.9°C 
1836 eGFP-65 for 71.2°C 
60.7°C 
1527 eGFP-65 rev 57.7°C 
1578 mRFP-23 for 62.5°C 
62.5°C 
1521 mRFP-23 rev 65.6°C 
3211 GAPDH for 74.7°C 
74.7°C 
3212 GAPDH rev 75.0°C 
The RT-PCR program started with an initial denaturation at 98°C for 30 s. Afterwards, 35 
cycles were applied consisting of a denaturation at 98°C for 10 s, an annealing of the oligo-
nucleotides at (annealing temperatures, Tab. 20) for 30 s, and an elongation of the DNA 
fragment at 72°C for 30 s/1 kb. The final elongation step was achieved at 72°C for 10 min 
followed, when necessary, by a hold time at 4°C. PCR products were stored at -20°C for 
further experiments. 
6.2.9 Immunoblot analysis 
For the detection of the fluorescent fusion proteins, infected MeWo cells of a T75 culture 
flask were scraped into 4 ml ice-cold PBS. The suspension was then centrifuged at 1500 rpm 
and 4°C for 15 min (A-4-44-rotor). Thereafter, the pellet was resuspended in 300 µl ice-cold 
RIPA-PIC buffer (Tab. 8) and then incubated on ice for 30 min. Cell debris was then 
centrifuged at 13,000 rpm and 4°C for 20 min (75003424-rotor). After that, the protein lysates 
were collected in 50 µl portions and stored, when needed, at -80°C. For the protein 
concentration measurement, the Quick Start Bradford protein-assay kit (Bio-Rad, München) 
was used. In brief, three samples of each protein lysate were tested in parallel by which 1 µl 
of each sample was added to 149 µl water and mixed with 150 µl Bradford dye reagent then 
incubated for 5 min at room temperature. The absorption was then spectrophotometrically 
measured at λ = 595 nm via Safire2 fluorimeter (TECAN, Crailsheim). 
For the Western blot analysis, approximately 50-70 µg of each protein lysate were heat-de-
natured in 1x Laemmli buffer with 2-mercaptoethanol at 95°C for 10 min before incubation on 
ice (Laemmli, 1970). As a positive control, protein lysates from MeWo cells infected with an 
mRFP-expressing VZV Oka strain (provided by Benedict Kaufer, Berlin) and lysates from 
HeLa cells transfected with an expression vector of eGFP-β-actin fusion protein (provided by 
Gregor Maschkowitz, Kiel) were used to control the expression of the mRFP and eGFP 
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moieties, respectively. As a negative control, protein lysates from uninfected MeWo and 
HeLa cells were tested. Proteins were separated according to their molecular masses by 
using 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) at 90 V and 400 W for 30 
min then at 110 V and 400 W for 90 min. Subsequently, the proteins were blotted onto nitro-
cellulose membranes (Merck Millipore) at 20 V and 400 W for 30 min then incubated in WB 
blocking buffer (Tab. 8) for 1 h at room temperature or overnight at 4°C. Under the same 
incubation conditions, anti-VZV-gI as a viral control, anti ß-actin as a cellular control, anti-
GFP, and anti-RFP antibodies (Tab. 17) were used for the proteins detection. After three to 
five washings with TBST buffer (Tab. 8) within 15 min, membranes were incubated with 
HRP-conjugated goat anti-rabbit or anti-mouse secondary antibody (Tab. 17) for 1 h at room 
temperature followed by washes as described above. Detection was completed using the 
SuperSignal West Pico and Femto chemiluminescence substrates (Thermo Scientific) and 
protein signals were monitored via LAS-3000 CCD camera system (Tab. 19). 
6.3 Cell biology methods 
6.3.1 Cell culture 
VZV-permissive human melanoma MeWo cells (ATCC-HTB-65) were cultivated in 25 ml D10 
medium (Tab. 13) in 175 cm2-flasks at 37°C, 5% CO2, and 95% relative humidity as pre-
viously described (Grose & Brunell, 1978). As the MeWo cells formed a confluent monolayer 
after 5-7 d, they were harvested by trypsinization and passaged at a ratio of 1:6 in new D10 
medium that was replaced by fresh D10 medium after further 3-4 d. In cultivated MeWo cells, 
BAC-cloned genomes were transfected for the reconstitution of the corresponding viruses. 
The infected MeWo cells were cocultivated with uninfected cells in different ratios and later 
on, as needed, were harvested by trypsinization, resuspended in PBS, and pelleted at 1200 
rpm for 10 min (A-4-44-rotor). The pellet containing the virus-infected MeWo cells was 
resuspended either in ice-cold FBS medium and stored in portions in 9% DMSO at -80°C for 
further experiments, or in lysis buffer (Tab. 10) as previously described for the PCR-analysis 
(6.2.2). The portions were frozen gradually at approximately 1°C per min using an 
isopropanol-box in a -80°C freezer, in order to prevent the MeWo cells from destruction by a 
too fast freezing process. 
6.3.2 BAC DNA transfection and virus reconstitution 
VZV-permissive MeWo cells were lipofected with the corresponding BAC-cloned genomes 
via Lipofectamine 2000 (Life technologies). First, permissive MeWo cells in 6 ml D10 medium 
were seeded in three wells of a 6-well cell culture plate at a concentration of 1.5 * 106 MeWo 
cells in each well (2 ml). Next day, the 90% confluent MeWo cells in each well were trans-
fected with 500 µl of the transfection solution after replacing the D10 medium with DMEM 
medium without additives (Tab. 12). The transfection solution is a mixture of two parts. The 
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first solution was prepared mixing 10 µl Lipofectamine 2000 and 240 µl OptiMEM for 5 min. 
Separately, the second solution was prepared mixing 4 µg BAC DNA in a total volume of 250 
µl OptiMEM. The transfection solution was prepared by mixing the first and second solutions 
and incubating the mixture for 20 min at room temperature, in order to allow the formation of 
DNA-harboring liposomes. The following day, the DMEM medium without additives was re-
placed by fresh D10 medium and the cell culture was incubated for another 24 h. At that 
time, the infected MeWo cells from the three wells were harvested via trypsinization, resus-
pended all together in 6 ml D10 medium, and finally cocultivated in 25 ml D10 medium in a 
175 cm2-flask. The first plaques were detectable under the microscope after approximately 5 
d of the last incubation. 
For the transfection via the electroporation-based nucleofection technique, 2 * 106 MeWo 
cells or 4-5 * 105 HFF cells were resuspended in 100 µl OptiMEM medium at room tempera-
ture. Thereafter, 5 µg of the BAC-DNA were added to the suspension in a 2 mm electropora-
tion-specific cuvette. The cuvette was then placed in the Amaxa-Nuleofector device using the 
program (T2O for MeWo cells), which allows the BAC-DNA to penetrate into the cell. Subse-
quently, the suspension was further cultivated in 2 ml fresh D10 medium in a well of a 6-well-
plate at 37°C and 5% CO2. The well was then daily monitored for CPE formation. 
6.3.3 Virus titration and replication kinetics 
Titration experiments for the wild-type and recombinant viruses were performed by a modify-
cation of previously published methods (Grose et al., 1979). In short, 2-3 x 105 MeWo cells 
were seeded in each well of a 24-well plate one d before and were inoculated with 500 μl of 
serially 10-fold diluted infected MeWo cells in quadruplicates. At 3 dpi, fluorescent cytopathic 
effects (CPEs) were counted under the Olympus fluorescence microscope IX80 (Tab. 19) 
and then calculated as PFU/ml considering the dilution factors. For the titration of the non-
fluorescent wild-type HJO virus, the indirect immunofluorescence method was applied by 
which HJO-infected MeWo cells in 24-well cell culture plates were prepared. At 3 dpi, the 
D10 medium was removed and the cells were rinsed once with 1x PBS and then fixed with 
2% paraformaldehyde in 1x PBS for 20 min. Afterwards, the fixed cells were rinsed twice with 
1x PBS and then permeabilized with 1% (w/v) saponin in 1x PBS for 5 min and then rinsed 
twice again with 1x PBS. The unspecific bonds were blocked with 10% (v/v) FBS in 1x PBS 
for 1 h. Thereafter, the cells were incubated for 1 h in a mixture of the primary anti VZV-gI 
antibody in 1x PBS (Tab. 17), 10% (v/v) FBS, and 0.02% sodium azide as a preservative. 
The cells were then rinsed three times with 1x PBS and PFU detection was achieved by the 
secondary antibody staining (Alexa Fluor 488, 1:1000) in 1x PBS (Tab. 17) with 10% (v/v) 
FBS for 1 h. Finally, the cells were rinsed thrice with 1x PBS, and the visualization and ana-
lysis of the detected PFUs were achieved by the Olympus fluorescence microscope IX81 
(Tab. 19). 
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The replication kinetics of the generated fluorescently tagged mutants in comparison to those 
of the wild-type HJO strain were performed by infecting the same number of VZV-permissive 
MeWo cells with equal PFU quantity of each viral variant. Accordingly, 50-60% confluent 
MeWo cells were seeded and infected with 100 PFU per well in a 6-well plate and simulta-
neously in a 24-well plate (for the titration at 0 dpi) per recombinant virus. Over 5 dpi, the in-
fected cells of the 6-well plates were washed gently with PBS, trypsinized, resuspended in 
D10 medium, sedimented at 1200 rpm for 10 min (A-4-44-rotor), resuspended in FBS, and 
stored in portions in 10% DMSO at -80°C. Later on, titration was carried out as described 
above in quadruplicates in 24-well plates. The replication kinetic analysis was performed 
independently in triplicate, in order to confirm the reliability of the results. 
6.3.4 Fluorescence imaging 
For confocal imaging of infected non-neuronal cells, MeWo and fibroblast cells were seeded 
and inoculated on coverslips. At 2 dpi, infected cells were washed with PBS and fixed with 
2% paraformaldehyde in PBS for 20 min. After two washes with PBS and Hoechst 33342 
nuclear staining (Thermo Scientific) for 20 min, the cells were washed again before mounted 
on glass slides with mounting medium without DAPI (Vectashield, Biozol, Eching, Germany). 
For extra TGN staining, anti golgin-97 antibody (Santa Cruz, Heidelberg, Germany) was 
applied using the indirect immunofluorescence method described above (6.3.3). Imaging was 
performed with the Olympus laser scanning confocal microscope FV1000 (Tab. 19), and 
images were processed with FV1000 viewer software (Version 02.0b). 
For confocal imaging of infected neurons, freshly prepared embryonic rat sensory neurons 
(see DRG cells preparation below, 6.3.5) were seeded in channels of µ-slide 60.4 (ibidi, Pla-
negg, Germany) coated with (poly-L-lysine (200 µg/ml) + laminin (20 µg/ml); Tab. 12) then 
co-cultivated with infected fibroblasts for 2 d in supplemented NBM (Tab. 13). At 2 dpi, infec-
ted cells were fixed with Zamboni’s fixative buffer (Tab. 13) for 20 min, washed with PBS, 
and permeabilized with 0.1% Triton-X100 in PBS for 5 min. After several washes, cells were 
incubated with blocking buffer (10% normal goat serum in PBS; Dianova, Hamburg, Germa-
ny) for 60 min. For the identification of neuronal cells, the mouse anti ß-III tubulin primary 
antibody was used and detected by Alexa Fluor 350 goat anti-mouse secondary antibody 
(Tab. 17). For the DNA and nuclear staining, TO-PRO-3 iodide (Thermo Scientific) was 
applied. The Zeiss laser scanning confocal microscope LSM 510 (Tab. 19) was used for 
image acquisition, and images were processed with the LSM Image Browser software and 
ImageJ software. 
6.3.5 Cell-free VZV preparation 
This experiment was modified based on several previous protocols (Bleymehl et al., 2011; 
Goodwin et al., 2013; Grose et al., 1979; Harper et al., 1998; Reichelt et al., 2009; Schmidt-
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Chanasit et al., 2008). Cells of approximately 50%-infected confluent HFF fibroblasts from 
eight to ten 175 cm2 flasks were scraped and collected in ice-cold PBS, then pelleted by 
centrifugation at 1500 rpm and 4°C for 15 min (A-4-44-rotor). Afterwards, the cells were 
resuspended in 4 ml of ice-cold PSGC buffer (Tab. 13). Cells were then disrupted by a 
Dounce homogenizer 30 times followed by a sonication step in ice-cold water-bath 3 times 
for 2 min each and 30 s breaks in between. For the best yield, approximately (105 PFU/ml), 
cell-free VZV and infectious debris together were portioned and stored at -80°C. 
6.3.6 Dorsal-root ganglia cells preparation and cultivation 
Preparation protocols and cultivation systems were adapted from published protocols (Bauer 
et al., 2014). Shortly, 18-d-old rat embryos (E18) were dissected from the uterus of pregnant 
Wistar rats shortly after CO2-euthanization. Immediately thereafter, E18 embryos were deca-
pitated and rinsed with ice-cold HBSS medium (Tab. 12). DRG cells were isolated after lami-
nectomy, then collected again in ice-cold HBSS. The sensory neurons were prepared after 
the dissociation of DRG cells by treatment with 2.5% trypsin in PBS (Tab. 12) for 30 min at 
37°C followed by trypsin inhibitor DTI (Tab. 12) treatment for 5 min at 37°C. DRG cells and/or 
dissociated sensory neurons were cultivated at 37°C and 5% CO2 in supplemented NBM 
(Tab. 13) which was occasionally replaced. 
6.3.7 Compartmentalized neuron cultivation systems 
ibidi µ-slides 60.4 were coated overnight at room temperature with a mixture of 400 µg/ml 
poly-L-lysine and 20 µg/ml laminin (Tab. 12) in water. After three washings and a final drying 
step, every channel between the pair of chambers was filled with 30 µl of 0.5% agarose (In-
vitrogen) in supplemented NBM without NGF, and then allowed to cool until agarose became 
completely solid. Subsequently, one to three freshly prepared ganglia were seeded into one 
chamber filled with 60 µl of supplemented NBM (Tab. 13), whereas the opposite chamber 
was filled with medium containing 10-fold higher NGF concentration (125 ng/ml) to accele-
rate axonal growth toward the distal chamber (Fig. 25A). After cultivation overnight at 37°C 
and 5% CO2, DRG cells were treated with 40 µl of 10 µM Ara-C (Tab. 12) for 2-3 d to termi-
nate the growth of ganglionic non-neuronal cells (Campenot, 1977). Hereafter, the medium 
was aspirated and the ganglia cells were further cultivated in a fresh supplemented NBM 
until axons reached the distal chamber. 
Anterograde and retrograde infections were initiated by cultivating DRG cells in 60 µl of 104-
105 PFU/ml of cell-free VZV at 37°C and 5% CO2. After 2-3 h, medium was replaced with 
fresh virus-free medium and axons were daily monitored to trace the colocalization of the 
fluorescently labeled proteins using the Keyence fluorescence microscope BZ-9000 (Tab. 
19). 
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An alternative compartmentalized cultivation system was developed using an ibidi chemo-
taxis µ-slide3D further improving the efficiency of the former protocol and providing an 
additional convenient method to study the axonal transport of VZV. In this system, 0.1% 
agarose in supplemented NBM without NGF was used, and axons were allowed to grow for 
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BAC bacterial artificial chromosome 
bp base pairs 
cDNA complementary DNA 
Cm chloramphenicol 
CPE cytopathogenic effect 
DAPI 4',6-diamidino-2-phenylindole 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTPs deoxyribonuclotide triphosphates 
dpi day post infection 
dpt day posttransfection 
DRG dorsal root ganglia 
dsDNA double-stranded deoxyribonucleic acid 
DTI defined trypsin inhibitor 
E early genes 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetic acid 
eGFP enhanced green fluorescent protein 
FBS fetal bovine serum 
for forward  
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
gI glycoprotein I 
HFF human foreskin fibroblasts 
HRP horseradish peroxidase 
HSV-1 herpes simplex virus type 1 
IE immediate early protein 
IRL internal repeat long 
IRS internal repeat short 
Kan kanamycin 
KanR kanamycin cassette 
kb kilo base pairs 
L late genes 
LB Luria Bertani broth 
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M marker, DNA ladder 
MeWo human melanoma cell line 
Mini-F minimal components of a fertility plasmid 
mRFP monomeric red fluorescent protein 
NBM neurobasal medium 
NGF nerve growth factor 
OD optical density 
Opti-MEM improved minimal essential medium MEM 
ORF open reading frame 
PAGE polyacrylamide gel electrophoresis 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PFU plaque forming unit 
pHJOpac plasmid of the European VZV wild-type isolate HJO 
PIC protease inhibitor cocktail 
PrV pseudorabies virus 
R repetitive region 
rev reverse 
RIPA radioimmunoprecipitation assay 
RFLP restriction fragment length polymorphism 
RNA ribonucleic acid 
rpm round per minute 
RT reverse transcriptase 
SDS sodium dodecyl sulfate 
TBE tris borate EDTA buffer 
TBS tris buffered saline 
TBST tris buffered saline with tween 
TGN trans Golgi network 
Tris tris(hydroxymethyl)aminomethane 
TRL terminal repeat long 
TRS terminal repeat short 
U unit 
UL unique long region 
US unique short region 
v/v volume per volume 
w/v weight per volume 
VZV varicella-zoster virus 
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